insert into [Precision_Medicine_Matching_System].[dbo].[DrugLabelAnnotation]
([Id]
      ,[Source]
      ,[DosingInformation]
      ,[SummaryMarkdown])
values
('PA166104775','U.S. Food and Drug Administration',0,'Although the atorvastatin (LIPITOR) drug label does not specifically mention genetic testing, one of the indications listed is for the treatment of familial hypercholesterolemia, a genetically determined condition caused by mutations in the low density lipoprotein receptor (LDLR); one of the drug''s mechanisms of action is increasing LDLR cell surface expression.'),
('PA166104776','U.S. Food and Drug Administration',0,'Warfarin (COUMADIN) is an anticoagulant used as a prophylaxis and to treat venous thrombosis, pulmonary embolism, thromboembolic complications from atrial fibrillation and cardiac valve replacement, and to reduce the recurrence of myocardial infarction. Pharmacogenomics-related dosing information for CYP2C9 and VKORC1 variants is provided within the label. The drug label notes that deficiency in protein C (PROC) or protein S (PROS1) have been associated with tissue necrosis following warfarin administration.'),
('PA166104777','U.S. Food and Drug Administration',0,'The FDA-approved drug label for clopidogrel (Plavix) warns that patients who are CYP2C19 poor metabolizers may have diminished effectiveness of the drug as compared to patients with normal CYP2C19 function. The drug label says to consider use of a different platelet P2Y12 inhibitor in patients identified as CYP2C19 poor metabolizers.'),
('PA166104778','U.S. Food and Drug Administration',0,'Brentuximab vedotin (ADCETRIS) is a CD30-directed antibody-drug conjugate indicated for treatment of patients with various lymphomas. The Clinical Studies section of the label notes the percentage of patients who were anaplastic lymphoma kinase (ALK) negative and positive in certain trials.'),
('PA166104779','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for indacaterol (Hirobriz Breezhaler) does not contain pharmacogenetic information, but does contain information regarding the pharmacodynamics of the drug as a beta2-adrenoceptor (ADRB2) agonist and also contains information regarding the pharmackinetics of indacaterol involving UGT1A1, CYP3A4 and ABCB1.'),
('PA166104780','U.S. Food and Drug Administration',0,'The FDA-approved label for carbamazepine (TEGRETOL) states screening of patients with ancestry in genetically at-risk populations (patients of Asian descent) for the presence of the HLA-B*1502 allele should be carried out prior to treatment due to a high risk of serious and something fatal dermatologic reactions. It also notes that a moderate association has been found between HLA-A*3101 and the risk of developing hypersensitivity reactions to carbamazepine, though it does not mention testing for this allele.'),
('PA166104781','U.S. Food and Drug Administration',0,'The FDA-approved drug label for dasatinib (SPRYCEL) notes that it is intended for adults or children with Philadelphia chromosome-positive chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (Ph+ ALL).'),
('PA166104782','U.S. Food and Drug Administration',0,'The FDA-approved drug label for azathioprine (IMURAN) states to consider genotyping or phenotyping patients for TPMT deficiency and genotyping for NUDT15 deficiency in patients with severe myelosuppression. Alternative therapy in patients with homozygous TPMT or NUDT15 deficiency and reduced dosages in patients with heterozygous deficiency should be considered.'),
('PA166104783','U.S. Food and Drug Administration',0,'The FDA-approved drug label for rasburicase (Elitek) states that is unclear whether patients with NADH cytochrome b5 reductase (CYB5R1, 2, 3, 4) deficiency are at risk for methemoglobinemia or hemolytic anemia. It also states that patients at higher risk for G6PD deficiency, such as those of African or Mediterranean ancestry, should be screened prior to starting treatment, as rasburicase is contraindicated in patients with G6PD deficiency.'),
('PA166104784','U.S. Food and Drug Administration',0,'The FDA-approved drug label for diazepam (Diastat) notes that the drug is metabolized by CYP2C19 and CYP3A4, and that inter-individual variation in clearance of the drug is likely attributable genetic polymorphism of CYP2C19 and CYP3A4.'),
('PA166104785','U.S. Food and Drug Administration',0,'Erlotinib (TARCEVA) is a kinase inhibitor indicated for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.'),
('PA166104786','U.S. Food and Drug Administration',0,'The FDA-approved drug label for chloroquine (ARALAN) states that it may cause hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals.'),
('PA166104787','U.S. Food and Drug Administration',0,'The FDA-approved drug label for cevimeline (EVOXAC) states that CYP2D6, CYP3A3 and CYP3A4 are responsible for the metabolism of cevimeline, and that cevimeline should be used with caution in individuals known or suspected to be CYP2D6 poor metabolizers, as they may be at a higher risk of adverse events.'),
('PA166104788','U.S. Food and Drug Administration',0,'The FDA-approved drug label for fluoxetine and olanzapine (SYMBYAX) states that individuals who are CYP2D6 poor metabolizers metabolized S-fluoxetine at a slower rate and achieved higher concentrations.'),
('PA166104789','U.S. Food and Drug Administration',0,'The FDA-approved drug label for gefinitib (IRESSA) states that it is indicated for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.'),
('PA166104790','U.S. Food and Drug Administration',0,'The decision of whether to treat patients with imatinib (GLEEVEC) is based on the presence of genetic biomarkers, including BCR-ABL (the Philadelphia chromosome), KIT, and PDGFR gene rearrangements.'),
('PA166104791','U.S. Food and Drug Administration',0,'Lapatinib (TYKERB) is indicated for patients with breast cancer whose tumors overexpress HER2 (ERBB2). The FDA-approved drug label for lapatinib notes that the HLA-DQA1*02:01 and HLA-DRB1*07:01 alleles have been associated with hepatotoxicity in individuals received the drug, but does not discuss genetic testing for these alleles.'),
('PA166104792','U.S. Food and Drug Administration',0,'Fulvestrant (FASLODEX) is used to treat hormone-receptor positive breast cancer.'),
('PA166104793','U.S. Food and Drug Administration',0,'The FDA-approved drug label for risperidone (PERSERIS) states that exposure to the total active moiety is similar in CYP2D6 extensive, intermediate and poor metabolizers, supporting no need for dose adjustment based on CYP2D6 genotype.'),
('PA166104794','U.S. Food and Drug Administration',0,'Sodium phenylacetate and sodium benzoate (AMMONUL) provides an alternate vehicle to urea for waste nitrogen excretion in patients with urea cycle disorders. Urea cycle disorders may be caused by mutations in the genes NAGS, CPS1, OTC, ASS1, ASL and ARG1.'),
('PA166104795','U.S. Food and Drug Administration',0,'The FDA-approved drug label for busulfan (MYLERAN) states it is less effective in patients with chronic myelogenous leukemia who lack the Philadelphia chromosome.'),
('PA166104796','U.S. Food and Drug Administration',0,'The FDA-approved label for trastuzumab emtansine (KADCYLA) states that test results demonstrating HER2 protein overexpression are required prior to initiating therapy with trastuzumab emtansine using FDA-approved tests by laboratories with demonstrated proficiency.'),
('PA166104797','U.S. Food and Drug Administration',0,'Letrozole (Femara) is indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. It is also indicated as a first-line treatment for advanced breast cancer in postmenopausal women with hormone receptor positive or unknown tumors, or for extended adjuvant treatment of post-menopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy.'),
('PA166104798','U.S. Food and Drug Administration',0,'The FDA-approved drug label for propranolol (INNOPRAN XL) states that no difference in clearance of the drug was observed between CYP2D6 extensive and poor metabolizers.'),
('PA166104799','U.S. Food and Drug Administration',0,'The FDA-approved label for tramadol (ULTRAM) states that individuals who are CYP2D6 ultra-rapid metabolizers convert tramadol into its active metabolite more rapidly than other people, and that even at labeled dosage regimens they may have life-threatening or fatal respiratory depression; these individuals should not use tramadol.'),
('PA166104800','U.S. Food and Drug Administration',0,'The FDA-approved drug label for indacaterol (ARCAPTA NEOHALER) states that steady-state AUC and Cmax of indacaterol were 1.2-fold higher in patients with the (TA)7/(TA)7 (*28/*28) genotype than in patients with the (TA)6/(TA)6 (*1/*1) genotype, suggesting no relevant effect of UGT1A1 genotype of indacaterol exposure.'),
('PA166104801','U.S. Food and Drug Administration',0,'The FDA-approved drug label for peginterferon alfa-2b (PEGINTRON) states that a single nucleotide polymorphism near the gene encoding interferon-lambda-3 (IL28B rs12979860) was associated with variable sustained viral response (SVR) rates. SVR rates by rs12979860 genotype were as follows: CC 66% vs. CT 30% vs. TT 22%.'),
('PA166104802','U.S. Food and Drug Administration',0,'The FDA-approved label for capecitabine (XELODA) notes that patients who have low or absent dihydropyrimidine dehydrogenase (DPD) activity are at increased risk for severe or fatal adverse reactions. However, the label does not mention genetic testing or screening for DPD activity.'),
('PA166104803','U.S. Food and Drug Administration',0,'The drug labeling for maraviroc (SELZENTRY) is not related to genetic testing of the patient, rather testing of the HIV-1 strain that has infected the patient. The FDA-approved label states that HIV tropism testing be carried out before treatment with maraviroc. This drug is indicated only for CCR5-tropic HIV-1 infection, and due to its mechanism of action, is not effective against CXCR4-tropic and dual-tropic HIV-1.'),
('PA166104804','U.S. Food and Drug Administration',0,'Tositumomab is used to treat patients with CD20-positive non-Hodgkin''s lymphoma. The drug is a monoclonal antibody that targets the CD20 antigen, but there is no association with genetic variation within the coding gene, MS4A1, and therefore no mention of genetic testing in the drug label. Please note that as of August 2013, tositumomab (Bexxar) is no longer being manufactured or sold. Labels for this drug are no longer available on Drugs@FDA or DailyMed.'),
('PA166104805','U.S. Food and Drug Administration',0,'Thioridazine is used to treat schizophrenia, but has been associated with Torsades de pointes and sudden death. Due to the potentially fatal side effects, it is typically reserved for patients who do not respond well to other anti-psychotics. This drug is contraindicated in patients with reduced CYP2D6 activity.'),
('PA166104806','U.S. Food and Drug Administration',0,'Tolterodine (DETROL) is used for the treatment of overactive bladder and is primarily metabolized by CYP2D6. Poor metabolizers may have greater plasma concentrations of the drug which could possibly have an effect QT interval.'),
('PA166104807','U.S. Food and Drug Administration',0,'Fluorouracil is available as both an injection and a topical cream (CARAC). These two formulations have different indications. Both FDA-approved labels contain information about the potential for severe toxicity in patients with dipyrimidine dehydrogenase (DPD) deficiency.'),
('PA166104808','U.S. Food and Drug Administration',0,'The FDA-approved drug label for nelfinavir (VIRACEPT) states that coadministration of nelfinavir and drugs that induce CYP3A or CYP2C19 may decrease nelfinavir plasma concentrations and reduce its therapeutic effect. Coadministration of nelfinavir and drugs that inhibit CYP3A or CYP2C19 may increase nelfinavir plasma concentrations.'),
('PA166104809','U.S. Food and Drug Administration',0,'The FDA-approved drug label for panitumumab (Vectibix) states that it is an EGFR antagonist indicated for the treatment of wild-type RAS (defined as wild-type in both KRAS and NRAS) metastatic colorectal cancer.'),
('PA166104810','U.S. Food and Drug Administration',1,'The FDA-approved drug label for mercaptopurine (PURIXAN) states that patients with severe myelosuppression should be evaluated for TPMT or NUDT15 deficiency, and that patients with homozygous TPMT or NUDT15 deficiency require substantial dose reductions.'),
('PA166104811','U.S. Food and Drug Administration',0,'The FDA-approved drug label for quinidine states that the drug inhibits the action of CYP2D6, effectively converting CYP2D6 extensive metabolizers into poor metabolizers. The drug label advises caution whenever quinidine is prescribed together with drugs metabolized by CYP2D6.'),
('PA166104812','U.S. Food and Drug Administration',0,'Protriptyline hydrochloride is an antidepressant agent and belongs to the class of tricyclic antidepressants. CYP2D6 poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.'),
('PA166104813','U.S. Food and Drug Administration',0,'The FDA-approved drug label for carvedilol (COREG) states that it is affected by the poor metabolizers of debrisoquin (a marker for cytochrome P450 2D6) resulting in higher plasma concentrations of R( + )-carvedilol. Additionally, CYP2D6 poor metabolizers had a higher rate of dizziness during up-titration.'),
('PA166104814','U.S. Food and Drug Administration',0,'The FDA-approved drug label for drospirenone and ethinyl estradiol (Yaz) notes that drospirenone did not affect the clearance of omeprazole, suggesting that it does not inhibit the CYP2C19 enzyme.'),
('PA166104815','U.S. Food and Drug Administration',0,'The FDA-approved drug label for clozapine (CLOZARIL) states that it may be necessary to reduce the dose in patients who are CYP2D6 poor metabolizers, as these individuals may develop higher than expected plasma concentrations of clozapine when given usual doses.'),
('PA166104816','U.S. Food and Drug Administration',0,'The FDA-approved drug label for esomeprazole (NEXIUM) notes that individuals who are CYP2C19 poor metabolizers may have double the steady state area under the plasma concentration-time curve (AUC) of esomeprazole compared to extensive metabolizers.'),
('PA166104817','U.S. Food and Drug Administration',0,'Tretinoin (VESANOID) is a derivative of vitamin A (retinol) used for the treatment of skin conditions and acute promyelocytic leukemia (APL). APL is characterized by the translocation t(15;17) and PML/RAR alpha (RARA) fusion protein.'),
('PA166104818','U.S. Food and Drug Administration',0,'The FDA-approved drug label for voriconazole (VFEND) states that CYP2C19 poor metabolizers have, on average, 4-fold higher voriconazole exposure as compared to normal metabolizers, while intermediate metabolizers have 2-fold higher exposure as compared to normal metabolizers.'),
('PA166104819','U.S. Food and Drug Administration',0,'Tamoxifen (SOLTAMOX) is an anti-estrogen used in the treatment and prevention of breast neoplasms, including those with estrogen receptor-positive breast cancer.'),
('PA166104820','U.S. Food and Drug Administration',0,'The FDA-approved drug label for doxepin (Silenor) notes that CYP2D6 and CYP2C19 poor metabolizers have higher than expected plasma levels of the drug when given typical doses. The FDA-approved drug label for doxepin cream (ZONALON) notes the genetic variability of the CYP2D6 enzyme and its effect on tricyclic antidepressants (TCAs).'),
('PA166104821','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for arsenic trioxide (TRISENOX) states that it is indicated for the induction of remission, and consolidation in adult patients with acute promyelocytic leukemia (APL) characterized by the presence of the t(15;17) translocation and/or the PML/RAR&alpha; gene.'),
('PA166104822','U.S. Food and Drug Administration',0,'The FDA-approved drug label for terbinafine (LAMISIL) states that the drug is an inhibitor of the CYP2D6 enzyme, and therefore may convert CYP2D6 extensive metabolizers to poor metabolizers.'),
('PA166104823','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for methylthioninium chloride Proveblue (also known as methylene blue) states that the drug is contraindicated in patients with G6PD deficiency due to risk of hemolytic anemia, and in patients with a deficiency in NADPH reductase (encoded by the BLVRB gene). The label also states that failure to respond to the drug may indicate a deficiency in cytochrome b5 reductase (CYB5R3) or G6PD.'),
('PA166104825','U.S. Food and Drug Administration',0,'The FDA-approved drug label for valproic acid (Depakene) notes that it is contraindicated in patients with known urea cycle disorders (UCDs), a group of uncommon genetic abnormalities, particularly ornithine transcarbamylase (OTC) deficiency.'),
('PA166104826','U.S. Food and Drug Administration',0,'Cetuximab (ERBITUX) is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of head and neck cancer, as well as K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved text.'),
('PA166104827','U.S. Food and Drug Administration',1,'The FDA-approved drug label for atomoxetine (STRATTERA) recommends a dose adjustment in children or adolescents who are CYP2D6 poor metabolizers, or who are administered strong CYP2D6 inhibitors. Additionally, the label notes a number of adverse events that occurred more frequently in CYP2D6 poor metabolizers than extensive metabolizers in clinical trials. Laboratory tests are available to identify CYP2D6 poor metabolizers.'),
('PA166104828','U.S. Food and Drug Administration',0,'Hydralazine hydrochloride and isosorbide dinitrate (BiDil) is metabolized by acetylation, and individuals who are ''fast acetylators'' may have decreased exposure to the drug, whereas individuals who are ''slow acetylators'' may have increased drug bioavailability. Acetylation status of an individual can be determined by examining genetic variants in the NAT2 gene. However, the label never mentions any specific gene with regard to acetylator status.'),
('PA166104829','U.S. Food and Drug Administration',1,'The FDA-approved drug label for tetrabenazine (XENAZINE) states that patients requiring doses above 50 mg per day should be genotyped for the drug metabolizing enzyme CYP2D6 to determine if the patient is a poor metabolizer (PM) or an extensive metabolizer (EM). People with CYP2D6 poor metabolizer genotypes should be treated with lower doses.'),
('PA166104830','U.S. Food and Drug Administration',0,'Tiotropium (SPIRIVA RESPIMAT) is an inhalation powder used daily for the treatment of bronchospasms associated with chronic obstructive pulmonary disease (COPD) and maintenance treatment of asthma. It is believed to be metabolized in part by CYP2D6.'),
('PA166104831','U.S. Food and Drug Administration',1,'The FDA-approved drug label for irinotecan (CAMPTOSAR) states that a reduction in the starting dose by at least one level of CAMPTOSAR should be considered for patients known to be homozygous for the UGT1A1*28 allele. The FDA-approved drug label for irinotecan (ONIVYDE) states that the recommended starting dose of ONIVYDE in patients homozygous for the UGT1A1*28 allele is 50mg/m2 administered by IV infusion over 90 minutes, with an increased dose to 70 mg/m2 as tolerated in subsequent cycles.'),
('PA166104832','U.S. Food and Drug Administration',0,'Carisoprodol (SOMA) should be used with caution in patients with reduced CYP2C19 activity. Published studies indicate that patients who are poor CYP2C19 metabolizers have a 4-fold increase in exposure to carisoprodol and a 50% decreased exposure to meprobamate (a metabolite of carisoprodol) compared to normal CYP2C19 metabolizers.'),
('PA166104833','U.S. Food and Drug Administration',0,'The FDA-approved label for abacavir (ZIAGEN) states that genetic testing for the HLA-B*5701 allele is required prior to initiating or reinitiating treatment with abacavir in patients of unknown HLA-B*5701 status. Abacavir is contraindicated in patients with the HLA-B*5701 allele due to risk for abacavir hypersensitivity reactions.'),
('PA166104834','U.S. Food and Drug Administration',0,'Lenalidomide (REVLIMID) is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.'),
('PA166104835','U.S. Food and Drug Administration',0,'Fluoxetine (PROZAC) is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder, obsessive compulsive disorder, bulimia nervosa, and panic disorder. Fluoxetine is metabolized by several cytochrome P450 enzymes with CYP2D6 being a major contributor.'),
('PA166104836','U.S. Food and Drug Administration',0,'The FDA-approved drug label for metoprolol (TOPROL-XL) states that is metabolized predominantly by CYP2D6, and that poor and extensive metabolizers who concomitantly use CYP2D6 inhibiting drugs will have increased metoprolol blood levels, decreasing metoprolol''s cardioselectivity.'),
('PA166104837','U.S. Food and Drug Administration',0,'The FDA-approved drug label for propafenone (RYTHMOL SR) states that administration of the drug to CYP2D6 slow and extensive metabolizers resulted in significant differences in plasma concentrations. However, the recommended dosing regimen of the drug is the same for all patients.'),
('PA166104838','U.S. Food and Drug Administration',1,'The FDA-approved drug label for thioguanine (TABLOID) says to consider testing for TPMT and NUDT15 deficiency in patients who experience severe bone marrow toxicities or repeated episodes of myelosuppression. It also says to reduce initial dosage in patients known to have homozygous TPMT or NUDT15 deficiency.'),
('PA166104839','U.S. Food and Drug Administration',1,'The FDA-approved drug labels for aripiprazole (ABILIFY and ABILIFY MAINTENA), provide dosage adjustments for patients who are CYP2D6 poor metabolizers (PMs). CYP2D6 PMs taking ABILIFY should receive half the usual dose, and CYP2D6 PMs taking ABILIFY MAINTENA should have their dose reduced to 300 mg from the recommended dose of 400 mg.'),
('PA166104840','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for lapatinib (Tyverb) states that it is indicated for the treatment of adult patients with breast cancer whose tumors overexpress HER2, in combination with various other drugs. This includes combination with trastuzumab for patients with hormone receptor-negative disease, and combination with an aromatase inhibitor for hormone receptor-positive disease.'),
('PA166104841','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for clopidogrel (Plavix) states that in patients who are CYP2C19 poor metabolizers, clopidogrel at recommended doses forms less of the active metabolite and has a smaller effect on platelet function. The EPAR also discusses literature on the effect of CYP2C19 metabolizer status on clopidogrel pharmacokinetics and antiplatelet response.'),
('PA166104842','U.S. Food and Drug Administration',0,'Nilotinib (Tasigna) is indicated for use in patients diagnosed with Philadelphia chromosome positive (presence of a BCR-ABL1 gene fusion) chronic myeloid leukemia, due to its mechanism of action.'),
('PA166104843','U.S. Food and Drug Administration',1,'The FDA-approved drug label for celecoxib (CELEBREX) states that in adult patients known or suspected to be poor CYP2C9 metabolizers, treatment should be initiated with half of the lowest recommended dose. In patients with juvenile rheumatoid arthritis (JRA) known or suspected to be poor CYP2C9 metabolizers, alternative treatments should be considered.'),
('PA166104844','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for erlotinib (Tarceva) states that it is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations, and switch maintenance treatment in patients with locally advanced or metastatic NSCLC with EGFR activating mutations and stable disease after first-line chemotherapy, among other indications.'),
('PA166104845','U.S. Food and Drug Administration',0,'The FDA-approved label for dapsone gel (ACZONE) states that some subjects with G6PD deficiency using ACZONE developed laboratory changes suggestive of hemolysis. The label states that dapsone gel (ACZONE) should be avoided in patients with congenital methemoglobinemia, which is associated with variants in CYB5R3.'),
('PA166104846','U.S. Food and Drug Administration',0,'The FDA-approved drug label for arsenic trioxide (TRISONEX) contains information regarding indication of the drug in patients whose acute promyelocytic leukemia (APL) is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.'),
('PA166104847','U.S. Food and Drug Administration',0,'The FDA-approved drug label for venlafaxine (Effexor XR) states that CYP2D6 poor metabolizers had increased levels of venlafaxine as compared to CYP2D6 extensive metabolizers.'),
('PA166104848','U.S. Food and Drug Administration',0,'The FDA-approved drug label for rabeprazole (ACIPHEX) provides evidence from a study showing that gastric acid suppression was higher in CYP2C19 poor metabolizers as compared to extensive metabolizers, possibly due to higher rabeprazole levels in poor metabolizers.'),
('PA166104850','U.S. Food and Drug Administration',0,'The FDA-approved drug label for rifampin, isoniazid and pyrazinamide (RIFATER) states that ''slow inactivators'' of isoniazid may be more susceptible to drug toxicity due to higher blood concentrations of the drug in these individuals. Acetylation status of an individual can be determined by examining genetic variants in the NAT2 gene. However, the label never mentions any specific gene with regard to inactivator or acetylator status.'),
('PA166104851','U.S. Food and Drug Administration',0,'Ticagrelor (BRILINTA) is a platelet inhibitor used to reduce the risk of thrombotic cardiovascular events for patients with acute coronary syndrome. The FDA-approved drug label notes that thrombotic cardiovascular events did not depend on CYP2C19 loss of function status.'),
('PA166104852','U.S. Food and Drug Administration',1,'The FDA-approved drug label for citalopram (CELEXA) recommends a maximum dose of 20 mg/day of citalopram in patients who are CYP2C19 poor metabolizers, due to the risk for QT prolongation. The label also states that citalopram steady state levels were not significantly different between CYP2D6 poor and extensive metabolizers.'),
('PA166104853','U.S. Food and Drug Administration',0,'The FDA-approved drug label for cisplatin states that genetic factors, such as variants in the TPMT gene, may contribute to cisplatin-induced ototoxicity. However, this association has not be consistent across populations and study designs.'),
('PA166104854','U.S. Food and Drug Administration',0,'The FDA-approved drug label for fluvoxamine (LUVOX) states that it appears to be metabolized, at least in part, by CYP2D6, and that caution should be used in treating patients with low CYP2D6 activity and those receiving other medication known to inhibit CYP2D6.'),
('PA166104855','U.S. Food and Drug Administration',0,'The FDA-approved drug label for boceprevir (Victrelis) contains information regarding a genetic variant near the IFNL3 gene (IL28B, rs12979860, a C to T change) which is a strong predictor of response to peginterferon alfa-2b (PegIntron) / ribavirin (Rebetol) treatment. Boceprevir must not be used as a monotherapy and should only be used in combination with these drugs for the treatment of chronic hepatitis C genotype 1.'),
('PA166104856','U.S. Food and Drug Administration',0,'The FDA-approved drug label for amitriptyline (ELAVIL) contains information regarding the metabolism of tricyclic antidepressants by CYP2D6: CYP2D6 poor metabolizers may have higher plasma concentrations of tricyclic antidepressants, and the label suggests monitoring of plasma levels if this drug is co-administrered with a CYP2D6 inhibitor.'),
('PA166104857','U.S. Food and Drug Administration',0,'Trimipramine (SURMONTIL) is a tricyclic antidepressant used to treat depression. Like many antidepressants, it has a black box warning for increased risk of suicidal thoughts and behavior. Trimipramine is metabolized by CYP2D6 and poor metabolizers my experience higher plasma concentrations of the drug at typical doses.'),
('PA166104858','U.S. Food and Drug Administration',0,'Vemurafenib (ZELBORAF) is a kinase inhibitor used to treat patients with unresectable or metastatic melanoma in cases where the BRAF V600E mutation is found by an FDA-approved test. In vitro evidence points to BRAF wild-type cells proliferation with exposure to BRAF inhibitors. Therefore, testing is required.'),
('PA166104859','U.S. Food and Drug Administration',0,'The FDA-approved drug label for crizotinib (XALKORI) states that it is indicated for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ALK or ROS1-positive as detected by an FDA-approved test.'),
('PA166104860','U.S. Food and Drug Administration',0,'The FDA-approved drug label for phenytoin (DILANTIN) states that limited evidence suggests that HLA-B*15:02 may be a risk factor for the development of Stevens-Johnson Syndrome/toxic epidermal necrolysis in patients of Asian ancestry taking antiepileptic drugs such as phenytoin. It also notes that the drug is metabolized by CYP2C9 and CYP2C19.'),
('PA166104862','U.S. Food and Drug Administration',0,'The FDA-approved drug label for desipramine (NORPRAMIN) notes that CYP2D6 poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs), such as desipramine, when given typical doses. Additionally, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. It is therefore desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be a CYP2D6 inhibitor.'),
('PA166104863','U.S. Food and Drug Administration',0,'The FDA-approved drug label for dexlansoprazole (DEXILANT) notes that systemic exposure of the drug is generally higher in CYP2C19 intermediate and poor metabolizers, as compared to extensive metabolizers.'),
('PA166104864','U.S. Food and Drug Administration',0,'The FDA-approved drug label for paroxetine (PEXEVA) states that it is both metabolized by and an inhibitor of CYP2D6. It also notes that when CYP2D6 extensive metabolizers were given paroxetine in combination with atomoxetine, atomoxetine steady state levels were higher than when the drug was given alone.'),
('PA166104866','U.S. Food and Drug Administration',0,'The FDA-approved drug label for pravastatin (PRAVACHOL) contains pharmacogenetic information regarding response results in patients with APOE genotype E2/E2 and Fredrickson Type III dysbetalipoproteinemia.'),
('PA166104867','U.S. Food and Drug Administration',0,'Among both treatment-naïve and previous treatment failures patients with HCV genotype 1 infections, subjects of all IL28B genotypes appeared to have higher SVR rates with telaprevir (INCIVEK)-containing regimens compared to PEG-IFN alpha and RBV only. Patients with the favorable IFNL3 genotype (rs12979860 CC) tend to have higher response rates (SVR) as compared to patients with the CT or TT genotype with the protease inhibitor combination in treatment naïve patients.'),
('PA166104868','U.S. Food and Drug Administration',0,'Modafinil (PROVIGIL), used to improve wakefulness, is metabolized by many cytochrome P450s. Patients that are poor metabolizers for CYP2D6 may need dose modifications for medications that have ancillary metabolism via CYP2C19, such as tricyclic antidepressants (TCAs).'),
('PA166104869','U.S. Food and Drug Administration',0,'The FDA-approved drug label for galantamine (RAZADYNE) states dosage adjustment of galantamine is not necessary in patients identified as CYP2D6 poor metabolizers as the dose is individually titrated to tolerability.'),
('PA166104870','U.S. Food and Drug Administration',1,'The FDA-approved drug label for pimozide (ORAP) states that CYP2D6 genotyping should be performed at doses above 0.05mg/kg/day in children or above 4 mg/day in adults. In poor CYP2D6 metabolizers, pimozide doses should not exceed 0.05mg/kg/day in children or 4 mg/day in adults and doses should not be increased earlier than 14 days.'),
('PA166104872','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for boceprevir (Victrelis) contains pharmacogenetic information regarding a genetic variant within the IL28B gene that is associated with response to treatment with peginterferon alfa-2b/ribavirin (drugs taken concomitantly with boceprevir), but highlight caveats in studies carried out so far and that the association with boceprevir is currently being investigated further. Please note that as of June 2018 boceprevir (Victrelis) has been withdrawn from use in the European Union.'),
('PA166104874','U.S. Food and Drug Administration',0,'Sulfamethoxazole and trimethoprim (BACTRIM) is used to prevent and treat infections caused by certain bacteria. The label warns that hemolysis may occur in G6PD deficient individuals. It also notes that patients who are &quot;slow acetylators&quot; may be more prone to idiosyncratic reactions to sulfonamides. Acetylation status of an individual can be determined by examining variants in the NAT2 gene. However, the label never mentions any specific gene with regard to acetylator status.'),
('PA166104875','U.S. Food and Drug Administration',0,'The FDA-approved drug label for clomipramine (Anafranil) notes that CYP2D6 poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs), such as clomipramine, when given typical doses.'),
('PA166104876','U.S. Food and Drug Administration',0,'The FDA-approved drug label for primaquine states that G6PD testing has to be performed before using the drug, and that it should not be prescribed for patients with severe G6PD deficiency.'),
('PA166104877','U.S. Food and Drug Administration',0,'Mycophenolic acid (Myfortic) is an IMPDH Inhibitor that should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndrome.'),
('PA166104878','U.S. Food and Drug Administration',0,'The FDA-approved drug label for methylene blue (PROVAYBLUE) states that it is contraindicated in patients with G6PD deficiency due to the risks of hemolytic anemia.'),
('PA166104879','U.S. Food and Drug Administration',0,'The FDA-approved drug label for imipramine (Tofranil-PM) states that CYP2D6 poor metabolizers have higher than expected plasma concentrations of TCAs when given usual doses.'),
('PA166104880','U.S. Food and Drug Administration',0,'The FDA-approved drug label for nefazodone states that treatment adjustment is not required based on CYP2D6 metabolizer status.'),
('PA166104881','U.S. Food and Drug Administration',0,'The FDA-approved drug label for glibenclamide (glyburide; GLYNASE PresTab) notes that caution should be used in patients with G6PD deficiency and a non-sulfonylurea alternative should be considered.'),
('PA166104882','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) highlights information regarding variation in the metabolism of desloratadine in different individuals, but does not mention pharmacogenetics or genetic testing. The genes/ enzymes involved are not known.'),
('PA166104883','U.S. Food and Drug Administration',0,'The FDA-approved drug label for denileukin diftitox (ONTAK) notes that it is indicated for patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor. Confirmation of malignant cells expressing CD25 is necessary prior to administration of the drug.'),
('PA166104884','U.S. Food and Drug Administration',1,'In patients known to be CYP2C19 poor metabolizers, the drug label states that the initial dose of clobazam (ONFI) should be 5 mg/day, and that dose titration should be proceed slowly according to weight.'),
('PA166104885','U.S. Food and Drug Administration',0,'Norfloxacin (NOROXIN) is used to treat urinary tract infections, sexually transmitted diseases and prostatitis caused by certain microorganisms. The label reports hemolytic reactions have been seen in G6PD deficient individuals in association with this drug.'),
('PA166104886','U.S. Food and Drug Administration',0,'The quinidine component of NUEDEXTA is a CYP2D6 inhibitor used to increase the plasma availability of dextromethorphan, which is metabolized by CYP2D6. CYP2D6 poor metabolizers may be at risk of experiencing toxicity.'),
('PA166104887','U.S. Food and Drug Administration',1,'The FDA-approved drug label for iloperidone (FANAPT) states that CYP2D6 poor metabolizers have higher exposure to iloperidone compared with extensive metabolizers, and they should have their dose reduced by one half.'),
('PA166104888','U.S. Food and Drug Administration',0,'The FDA-approved drug label for nortriptyline (Pamelor), a tricyclic antidepressant (TCA), states that CYP2D6 poor metabolizers have higher than expected plasma concentrations of TCAs when given usual doses.'),
('PA166104889','U.S. Food and Drug Administration',0,'Pertuzumab (PERJETA) is a targeted antibody drug designed to bind to ERBB2 (HER2). Detection of HER2 protein overexpression is necessary for selection of patients appropriate for PERJETA therapy because these are the only patients studied and for whom benefit has been shown.'),
('PA166104890','U.S. Food and Drug Administration',0,'Ivacaftor (KALYDECO) is indicated for the treatment of patients with cystic fibrosis (CF) who have a mutation in the CFTR gene that is responsive to ivacaftor based on clinical or in vitro data. Genetic testing is required prior to initiating treatment with ivacaftor if a patient''s CFTR genotype is not known.'),
('PA166104891','U.S. Food and Drug Administration',0,'Nalidixic acid (NegGram) is used to treat urinary tract infections due to gram-negative bacteria. Although the nalidixic acid drug label does not specifically mention genetic testing, the FDA highlight precaution prior to initiating treatment with nalidixic acid for G6PD deficient individuals due to an association with hemolytic anemia.'),
('PA166104892','U.S. Food and Drug Administration',0,'Sulfasalazine (Azulfidine) is used to treat and prolong remission for ulcerative colitis. The label warns that people with G6PD are susceptible to hemolytic anemia on this drug. The label also notes that acetylator status may affect metabolism of the drug and risk for adverse events; acetylation status of an individual can be determined by examining genetic variants in the NAT2 gene. However, the label never mentions any specific gene with regard to inactivator or acetylator status.'),
('PA166104893','U.S. Food and Drug Administration',0,'The FDA-approved drug label for perphenazine (TRILAFON) states that its metabolism is mediated by the CYP2D6 enzyme, and that CYP2D6 poor metabolizers will metabolize the drug more slowly and experience higher concentrations as compared with normal metabolizers. This may lead to greater side effects.'),
('PA166104894','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for rasburicase (Fasturtec) states that it is contraindicated in patients with G6PD deficiency due to a risk of hemolytic anemia or methemoglobinemia. Testing or screening for G6PD deficiency is not mentioned.'),
('PA166104895','U.S. Food and Drug Administration',0,'Erythromycin ethylsuccinate and sulfisoxazole acetyl is used to treat acute otitis media in children caused by certain strains of Haemophilus influenzae. The label warns that hemolysis may occur in G6PD deficient patients on this drug.'),
('PA166104896','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for abacavir (Ziagen) states that screening for the HLA-B*5701 allele should be performed in any HIV-infected patient, and that the drug should not be used in patient''s with the HLA-B*57:01 allele.'),
('PA166104897','U.S. Food and Drug Administration',0,'MoviPrep, a solution containing Vitamin C, is a laxative used for colon cleansing in preparation for a colonoscopy. Because it contains Vitamin C (ascorbic acid), the label warns that hemolytic reactions are possible in those with G6PD deficiency.'),
('PA166104898','U.S. Food and Drug Administration',0,'The FDA-approved drug label for lansoprazole (PREVACID) states that it is metabolized mainly by CYP3A and CYP2C19 isozymes. Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19'),
('PA166104899','European Medicines Agency',1,'The EMA European Public Assessment Report (EPAR) for aripiprazole (Abilify Maintena) states that the starting and maintenance dose should be 300 mg in known CYP2D6 poor metabolizers. The EMA EPAR for aripiprazole (ABILIFY) states that the mean elimination half-life for the drug is approximately 75 hours in CYP2D6 extensive metabolizers and 146 hours in CYP2D6 poor metabolizers, but does not provide any dosing advice based on CYP2D6 metabolizer status.'),
('PA166104900','U.S. Food and Drug Administration',0,'The FDA-approved drug label for pegloticase (KRYSTEXXA) states that patients at risk for G6PD deficiency should be screened prior to starting treatment, and that the drug should not be administered to patients with G6PD deficiency.'),
('PA166104901','U.S. Food and Drug Administration',0,'The FDA-approved drug label for pantoprazole (PROTONIX) states that pediatric patients who are CYP2C19 poor metabolizers exhibited ~10-fold lower clearance of the drug as compared to extensive metabolizers, and that a dose reduction should be considered in these patients. No dosage adjustment is needed in adult CYP2C19 poor metabolizers.'),
('PA166104902','U.S. Food and Drug Administration',0,'Sulfadiazine (SILVADENE) is an antimicrobial topical drug used to prevent and treat wound sepsis in second and third degree burns. A link between sulfadiazine-induced hemolytic anemia and G6PD deficiency is highlighted in the Warnings section of the label.'),
('PA166104903','U.S. Food and Drug Administration',0,'Nitrofurantion (Furadantin) is used to treat urinary tract infections caused by certain strains of bacteria. A link between nitrofurantoin-induced hemolytic anemia and G6PD deficiency is highlighted in the Warnings section.'),
('PA166104904','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for brentuximab vedotin (ADCETRIS) states that it is indicated for adult patients with CD30+ Hodgkin lymphoma (HL) or CD30+ cutaneous T-cell lymphoma (CTCL), among other indications. CD30 is encoded by the TNFRSF8 gene.'),
('PA166104905','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for capecitabine (Xeloda) states that it is contraindicated in patients with complete absence of DPD activity, and that genotyping for certain alleles is recommended to identify patients at increased risk for severe toxicity. It also states that a reduction in starting dose in patients with partial DPD deficiency may be considered to avoid serious toxicity.'),
('PA166104906','U.S. Food and Drug Administration',0,'Probenecid is used to treat chronic gouty arthritis. An association between probenecid-induced hemolytic anemia and G6PD deficiency is highlighted in the Adverse Reactions section of the probenecid label.'),
('PA166104907','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) states that caution should be taken when administering eltrombopag in patients with known risk factors for thromboembolism, including Factor V Leiden (F5 gene) and ATIII deficiency (SERPINC1 gene).'),
('PA166104908','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for cetuximab (Erbitux) states that it is indicated for patients with EGFR-expressing, RAS wild-type metastatic colorectal cancer, among other indications.'),
('PA166104909','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for crizotinib (XALKORI) states that it is indicated for ALK-positive advanced non-small cell lung cancer (NSCLC) and ROS1-positive NSCLC.'),
('PA166104911','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for everolimus (Afinitor) states that it is indicated for hormone receptor-positive HER2/neu negative advanced breast cancer in combination with exemestane in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor, among other indications.'),
('PA166104912','U.S. Food and Drug Administration',0,'The FDA-approved drug label for eltrombopag (PROMACTA) notes that patients taking the drug have an increased risk of thromboembolism if they have antithrombin III deficiency (SERPINC1) or Factor V Leiden (F5).'),
('PA166104913','U.S. Food and Drug Administration',0,'Everolimus (AFINITOR) is indicated for treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole.'),
('PA166104914','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for dasatinib (SPRYCEL) states that it is indicated for adults or children with Philadelphia chromosome-positive chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (Ph+ ALL).'),
('PA166104915','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for olanzapine (Zalasta) contains information regarding the metabolism of the drug by the enzymes CYP1A2 and CYP2D6: factors that induce or inhibit CYP1A2 may alter the concentration of olanzapine and thus may require dosage monitoring. The EPAR does not mention pharmacogenetics or testing of genetic variants in these genes.'),
('PA166104916','U.S. Food and Drug Administration',0,'The FDA-approved drug label for codeine states in a black box warning that respiratory depression and death have occurred in children who received codeine following a tonsillectomy and/or adenoidectomy and who had evidence of being CYP2D6 ultra-rapid metabolizers. The label also states that individuals who are CYP2D6 ultra-rapid metabolizers should not use codeine.'),
('PA166104917','U.S. Food and Drug Administration',0,'The FDA-approved drug label for prasugrel (Effient) contains information regarding a lack of effect of genetic variants on prasugrel pharmacokinetics.'),
('PA166104919','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for fulvestrant (Faslodex) states that it is indicated for the treatment of estrogen-receptor positive, locally advanced or metastatic breast cancer in postmenopausal women, and, in combination with palbociclib for hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.'),
('PA166104920','U.S. Food and Drug Administration',0,'Trastuzumab (Herceptin) is used for the treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Select patients for therapy based on an FDA-approved companion diagnostic for Herceptin.'),
('PA166104921','U.S. Food and Drug Administration',0,'The FDA-approved drug label for omeprazole (PRILOSEC) notes that CYP2C19 is involved in the metabolism of the drug, and that poor metabolizers have a greater systemic exposure to omeprazole, followed by intermediate and then extensive metabolizers.'),
('PA166104922','U.S. Food and Drug Administration',1,'The FDA-approved drug label for flurbiprofen (ANSAID) states that patients known or suspected to be CYP2C9 poor metabolizers should receive a reduced dose of flurbiprofen to avoid abnormally high plasma levels.'),
('PA166104923','U.S. Food and Drug Administration',0,'Exemestane (AROMASIN) is an aromatase inhibitor indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy, or for treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.'),
('PA166104926','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for imatinib (Glivec) contains pharmacogenetic information regarding the indication of the drug in patients with tumors positive for biomarkers including KIT (CD117), BCR-ABL (Philadelphia chromosome), PDGFR and FIP1L1-PDGFR&alpha; rearrangements.'),
('PA166104927','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for lenalidomide (Revlimid) contains information regarding the inhibition of hematopoietic tumor cells that include those with chromosome 5 deletions.'),
('PA166104928','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) states that ivacaftor (Kalydeco) is indicated for cystic fibrosis patients who have one of the following variants in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, R117H. Treatment in patients who do not have one of these variants is not recommended, and if a patient''s genotype is not known, testing should be carried out before treatment.'),
('PA166104930','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for gefitinib (IRESSA) states that it is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK.'),
('PA166105010','U.S. Food and Drug Administration',0,'Duloxetine (CYMBALTA) is metabolized by CYP2D6 and CYP1A2. The FDA-approved drug label notes that concomitant administration of duloxetine and fluvoxamine (a potent CYP1A2 inhibitor) to CYP2D6 poor metabolizers resulted in a 6-fold increase in duloxetine AUC and Cmax.'),
('PA166105012','U.S. Food and Drug Administration',0,'The FDA-approved drug label for escitalopram (Lexapro) notes that escitalopram exposure under a supratherapeutic 30 mg dose is similar to the steady state concentrations expected in CYP2C19 poor metabolizers following a therapeutic dose of 20 mg. The label also comments on the relationship between CYP2D6 and escitalopram.'),
('PA166105023','U.S. Food and Drug Administration',0,'The FDA-approved drug label for rosuvastatin (CRESTOR) states that higher plasma concentrations of the drug have been seen in small groups of patients homozygous for the SLCO1B1 rs4149056 variant.'),
('PA166105028','U.S. Food and Drug Administration',0,'The FDA-approved drug label for nebivolol (BYSTOLIC) states that, though it is metabolized by CYP2D6, no dose adjustments are necessary for CYP2D6 poor metabolizers, as the clinical effect and safety profile was similar between poor and extensive metabolizers.'),
('PA166105058','U.S. Food and Drug Administration',0,'The FDA-approved drug label for pazopanib (VOTRIENT) states that patients with the UGT1A1 *28/*28 genotype had a significantly increased incidence of hyperbilirubinemia when taking pazopanib, as compared to those with the *1/*1 or *1/*28 genotype. Additionally, ALT &gt; 3 x ULN and ALT &gt; 5 x ULN both occurred more often in carriers of the HLA-B*57:01 allele as compared to non-carriers.'),
('PA166105059','U.S. Food and Drug Administration',0,'Ofatumumab (ARZERRA) is used to treat patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. The drug is a CD20-directed cytolytic monoclonal antibody, but there is no association with genetic variation within the coding gene, MS4A1, and therefore no mention of genetic testing in the drug label.'),
('PA166105070','U.S. Food and Drug Administration',0,'Anastrozole (ARIMIDEX) is an aromatase inhibitor indicated for use in postmenopausal women as an adjuvant treatment for hormone receptor-positive early breast cancer, as a first-line treatment for hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer, or to treat advanced breast cancer with disease progression following tamoxifen therapy.'),
('PA166105113','U.S. Food and Drug Administration',0,'The FDA-approved drug label for donepezil (ARICEPT) states that it is metabolized by the CYP2D6 and CYP3A4 enzymes, and that there are differences in clearance values among CYP2D6 poor, extensive and ultra-rapid metabolizers.'),
('PA166105117','U.S. Food and Drug Administration',0,'The FDA-approved drug label for efavirenz (SUSTIVA) states that efavirenz concentrations were higher in patients with the CYP2B6*6/*6 genotype as compared to the *1/*1 genotype, and that a positive relationship between increased efavirenz concentrations and QTc prologation has been observed.'),
('PA166105147','U.S. Food and Drug Administration',0,'The FDA-approved drug label for glimepiride (AMARYL) states that caution should be used in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency due to the risk for hemolytic anemia, and that a non-sulfonylurea alternative should be considered in this subset of patients. G6PD deficiency is a condition caused by variants in the G6PD gene which can be determined by enzymatic or genetic tests, however the drug label does not specifically mention testing.'),
('PA166105148','U.S. Food and Drug Administration',0,'The FDA-approved drug label for glipizide (GLUCOTROL) states that caution should be used in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency due to the risk for hemolytic anemia, and that a non-sulfonylurea alternative should be considered in this subset of patients. G6PD deficiency is a condition caused by variants in the G6PD gene which can be determined by enzymatic or genetic tests, however the drug label does not specifically mention testing.'),
('PA166105178','U.S. Food and Drug Administration',0,'The FDA-approved drug label for ORAQIX (lidocaine and prilocaine) states that patients with G6PD deficiency or congenital or idiopathic methemoglobinemia are more susceptible to drug-induced methemoglobinemia.'),
('PA166105195','U.S. Food and Drug Administration',0,'Metoclopramide (reglan) is indicated as a short-term treatment for adults with gastroesophageal reflux who fail to respond to conventional therapy. The FDA-approved drug label for metoclopramide notes that patients with NADH-cytochrome b5 reductase deficiency have an increased risk of developing methemglobinemia and/or sulfhemoglobinemia when treated with metoclopramide. The label and FDA table also mention G6PD; patients with G6PD deficiency experiencing metoclopramide-induced methemoglobinemia should not be given methylene blue.'),
('PA166105211','U.S. Food and Drug Administration',0,'The FDA-approved drug label for ondansetron (ZOFRAN) states that the drug is a substrate for CYP2D6 (among other CYP enzymes), but is likely that CYP2D6 genetic deficiency will result in little change in the rate of ondansetron elimination.'),
('PA166105213','U.S. Food and Drug Administration',0,'The FDA-approved drug label for oxcarbazepine (OXTELLAR XR) states that testing for the presence of the HLA-B*1502 allele should be considered in patients with ancestry in genetically at-risk populations prior to initiating treatment with the drug, due to the risk for Stevens-Johnson syndrome or toxic epidermal necrolysis.'),
('PA166105222','U.S. Food and Drug Administration',0,'The FDA-approved drug label for piroxicam (FELDENE) states that CYP2C9 intermediate and poor metabolizers had higher systemic levels of piroxicam as compared to normal metabolizers, and that known or suspected CYP2C9 poor metabolizers should consider a dose reduction.'),
('PA166105232','U.S. Food and Drug Administration',0,'The FDA-approved drug label for quinine (QUALAQUIN) previously had language to contraindicate the drug in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. This contraindication was removed in 6/2019 and replaced with language recommending monitoring for hemolytic anemia during treatment. The label also mentions CYP2D6 poor metabolizers in the context of drug-drug interactions with desipramine.'),
('PA166105240','U.S. Food and Drug Administration',0,'Rituximab (Rituxan) is used to treat patients with non-Hodgkin''s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis or granulomatosis polyangiitis and microscopic polyangiitis. The drug is a CD20-directed cytolytic monoclonal antibody, but there is no association with genetic variation within the coding gene, MS4A1, and therefore no mention of genetic testing in the drug label.'),
('PA166105315','European Medicines Agency',0,'Note: this medication has been withdrawn from use in the European Union'),
('PA166105319','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for panitumumab (Vectibix) states that it is indicated for adult patients with wild-type RAS metastatic colorectal cancer.'),
('PA166105321','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for prasugrel (Efient) contains information regarding the lack of effect of genetic variants in the CYP3A5, CYP2B6, CYP2C9 and CYP2C19 genes on the pharmacokinetics of prasugrel or response.'),
('PA166105334','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for nilotinib (Tasigna) states it is indicated for patients who have Philadelphia chromosome-positive (presence of a BCR-ABL1 gene fusion) chronic myelogenous leukemia (CML). The label differs from that of the FDA as it does not contain any information regarding UGT1A1 genotype.'),
('PA166114317','U.S. Food and Drug Administration',0,'Sodium phenylbutyrate (BUPHENYL) is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS).'),
('PA166114378','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for telaprevir (Incivo) contains a table showing higher SVR rates for patients with the IL28B (IFNL3) CC genotype compared to those with CT or TT when treated with the telaprevir, peginterferon alfa-2a and ribavirin drug combination, though this is not discussed further in the main text. Please note that as of September 2016 telaprevir (Incivo) has been withdrawn from use in the European Union.'),
('PA166114381','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for sodium phenylbutyrate (AMMONAPS) states that it is indicated as an adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase (CPS1), ornithine transcarbamylase (OTC) or argininosuccinate synthetase (ASS1).'),
('PA166114382','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for ticagrelor (Brilique) contains information regarding a study in which CYP2C19 and ABCB1 genotyping was carried out (PLATO - platelet inhibition and patient outcomes). In patients with one or more CYP2C19 loss of function allele, non-coronary artery by-pass grafting (non-CABG) PLATO major bleeding was increased when treated with ticagrelor compared to clopidogrel, but was similar in patients with no loss of function alleles.'),
('PA166114481','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for trastuzumab (Herceptin) requires testing of tumours for HER2 overexpression or gene amplification prior to initiating therapy. Trastuzumab (Herceptin) targets human epidermal growth factor receptor 2 (HER2) to inhibit growth of HER2 overexpressing cancer cells.'),
('PA166114482','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for vemurafenib (Zelboraf) requires testing of tumours for the BRAF V600 mutation prior to initiating treatment.'),
('PA166114903','U.S. Food and Drug Administration',0,'Afatinib (GILOTRIF) is indicated for patients with metastatic non-small cell lung cancer (NSCLC) who have tumors with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test.'),
('PA166114905','U.S. Food and Drug Administration',0,'Belimumab (BENLYSTA) is a human IgG1lambda monoclonal antibody, indicated for use in adults with active, autoantibody-positive, systemic lupus erythematosus who are receiving standard therapy. It acts by blocking binding of soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B-cell survival factor, to its receptors on B cells.'),
('PA166114907','U.S. Food and Drug Administration',0,'The FDA-approved drug label for bosutinib (BOSULIF) notes that it is intended for adults with newly-diagnosed chronic phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) or chronic, accelerated or blast phase Ph+ CML with resistance or intolerance to prior therapy.'),
('PA166114908','U.S. Food and Drug Administration',0,'Carglumic acid (Carbaglu) is a synthetic structural analogue of N-acetylglutamate (NAG), and is indicated as adjunctive therapy for the treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency or maintenance therapy for treatment of chronic hyperammonemia due to NAGS deficiency.'),
('PA166114910','U.S. Food and Drug Administration',0,'The FDA-approved drug label for chlorpropamide (DIABINESE) states that caution should be used in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency due to the risk for hemolytic anemia, and that a non-sulfonylurea alternative should be considered in this subset of patients.'),
('PA166114912','U.S. Food and Drug Administration',0,'The drug label for dabrafenib (TAFINLAR) states that it is indicated, as a single agent or in combination with trametinib, for patients with melanoma, non-small cell lung cancer (NSCLC) or anaplastic thyroid cancer (ATC) and the BRAF V600E or V600K mutations; the drug is not indicated for treatment of patients with wild-type BRAF melanoma, NSCLC or ATC.'),
('PA166114913','U.S. Food and Drug Administration',0,'The drug label for dabrafenib (TAFINLAR) states that it is indicated, as a single agent or in combination with trametinib, for patients with certain types of cancer. The label also notes that patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency have a risk for developing hemolytic anemia, and that these patients should be closely observed when taking dabrafenib.'),
('PA166114921','U.S. Food and Drug Administration',0,'Ibritumomab tiuxetan (Zevalin) is used to treat patients with B-cell non-Hodgkin''s lymphoma. The drug is a CD20-directed radiotherapeutic antibody, but there is no association with genetic variation within the coding gene, MS4A1, and therefore no mention of genetic testing in the drug label.'),
('PA166114923','U.S. Food and Drug Administration',0,'Lomitapide (JUXTAPID) is indicated as an adjunct to a low-fat diet and other lipid lowering treatments in patients with homozygous familial hypercholesterolemia (HoFH). Mutations in the LDL receptor gene (LDLR) are the most common cause of HoFH, however, mutations in other genes (such as APOB) can also lead to HoFH.'),
('PA166114926','U.S. Food and Drug Administration',0,'The FDA-approved drug label for mafenide (SULFAMYLON) mentions that fatal hemolytic anemia with disseminated intravascular coagulation has been reported following treatment with SULFAMYLON cream, possibly due to a glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD deficiency is a condition caused by variants in the G6PD gene which can be determined by enzymatic or genetic tests. However, the drug label does not specifically mention testing.'),
('PA166114928','U.S. Food and Drug Administration',0,'Mipomersen (KYNAMRO) is indicated as an adjunct to diet and lipid lowering treatments in patients with homozygous familial hypercholesterolemia (HoFH). Mutations in the LDL receptor gene (LDLR) are the most common cause of HoFH, however, mutations in other genes (such as APOB) can also lead to HoFH.'),
('PA166114930','U.S. Food and Drug Administration',0,'The FDA-approved drug label for omacetaxine (homoharringtonine; SYNRIBO) notes that it is intended for adults with chronic or accelerated phase chronic myeloid leukemia (CML). The majority of patients with CML are positive for the Philadelphia chromosome (BCR-ABL1 gene fusion).'),
('PA166114931','U.S. Food and Drug Administration',0,'The FDA-approved drug label for ponatinib (Iclusig) states that it is intended for adults with chronic, accelerated or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to prior tyrosine kinase inhibitor therapy, including those with the BCR-ABL T315I mutation. The majority of patients with CML are positive for the Philadelphia chromosome (BCR-ABL1 gene fusion).'),
('PA166114941','U.S. Food and Drug Administration',0,'The FDA-approved drug label for pravastatin (PRAVACHOL) states that the drug is intended for patients with familial hypercholesterolemia (Fredrickson Type IIa), among other indications. Familial hypercholesterolemia is commonly caused by mutations in the LDLR (low density lipoprotein receptor) gene; pravastatin has only been evaluated in patients with heterozygous familial hypercholesterolemia (i.e. patients with only one abnormal copy of the LDLR gene).'),
('PA166114944','U.S. Food and Drug Administration',0,'The FDA-approved drug label for regorafenib (STIVARGA) states that it is intended for patients with metastatic colorectal cancer who were previously given fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if they were RAS wild type, an anti-EGFR therapy.'),
('PA166115362','U.S. Food and Drug Administration',0,'Sodium nitrite is intended for sequential use with sodium thiosulfate, in order to treat acute and life-threatening cyanide poisoning. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency who are treated with sodium nitrite are at risk for a hemolytic crisis. Consideration should also be given for patients at increased risk for methemoglobinemia such as those with variants in CYB5R3.'),
('PA166115363','U.S. Food and Drug Administration',0,'Succimer (CHEMET) is used for treating lead poisoning in pediatric patients with blood lead levels greater than 45 mcg/dL. The drug label notes that succimer has been used to treat five patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency without any adverse reactions.'),
('PA166115365','U.S. Food and Drug Administration',0,'Trametinib (MEKINIST) is indicated for use in patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, or metastatic non-small cell lung cancer with BRAF V600E mutation, as detected by an FDA-approved test.'),
('PA166115367','U.S. Food and Drug Administration',0,'Velaglucerase alfa (VPRIV) is indicated as a long-term enzyme replacement therapy for patients with type 1 Gaucher disease. Gaucher disease is caused by mutations in the GBA gene, resulting in a deficiency of the enzyme beta-glucocerebrosidase. Velaglucerase alfa has the same amino acid sequence as naturally occurring glucocerebrosidase.'),
('PA166115435','European Medicines Agency',0,'The EMA EPAR for timolol contains information regarding potentiated beta-blockade when treatment is combined with CYP2D6 inhibitors. No pharmacogenetic information was found in the label.'),
('PA166117941','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for bosutinib (Bosulif) states that it is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myelogenous leukemia.'),
('PA166119823','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for afatinib (GIOTRIF) states that it is indicated for the treatment of EGFR TKI-naive adult patients with locally advanced or metastatic non-small cell lung cancer with activating EGFR mutations, among other indications.'),
('PA166119824','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for belimumab (Benlysta) contains information regarding its mechanism of action for use in the treatment of systemuc lupus erythematosus (SLE). It is a human IgG1lambda that blocks binding of TNFSF13B to its receptor to inhibit B cell survival and reduce differentiation.'),
('PA166119825','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for carglumic acid (Carbaglu) states that it is indicated in the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) primary deficiency, among other indications.'),
('PA166119826','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for dabrafenib (Tafinlar) states that it is indicated for patients with melanoma or non-small cell lung cancer with the BRAF V600 mutation.'),
('PA166119827','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for dextromethorphan and quinidine (Nuedexta) does not require dose adjustment based on CYP2D6 genotype. Efficacy is not expected to be affected in CYP2D6 poor metabolizers, however adverse reactions to quinidine are possible. Dextromethorphan is rapidly metabolized in CYP2D6 ultrametabolizers, and may result in subtherapeutic concentrations. Please note that as of February 2016 dextromethorphan and quinidine (Nuedexta) has been withdrawn from use in the European Union.'),
('PA166120286','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for esomeprazole (Nexium Control) notes that CYP2C19 poor metabolizers have higher plasma concentrations of the drug compared to extensive metabolizers, but there are no implications for dosing.'),
('PA166120287','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for norelgestromin and ethinyl estradiol (EVRA) states that it is contraindicated in patients with known hereditary or acquired predisposition for venous thromboembolism, including Factor 5 Leiden (F5), antithrombin-III deficiency (SERPINC1), protein C deficiency (PROC) and protein S deficiency (PROS).'),
('PA166120370','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for pioglitazone and glimepiride (Tandemact) states that caution should be taken in patients with G6PD deficiency as glimepiride is a sulfonylurea agent and a non-sulfonylurea alternative should be considered.'),
('PA166121246','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for ibritumomab (Zevalin) contains information regarding the indication of the drug for the treatment of CD20+ (MS4A1) follicular B-cell non-Hodgkin''s lymphoma due to its mechanism of action.'),
('PA166121250','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for lomitapide (Lojuxta) states it is indicated only for use in adult patients with homozygous familial hypercholesterolaemia and that genetic conformation should be obtained when possible. Genetic tests include screening for variants in the LDLR, APOB and PCSK9 genes (see the Genetic Test Registry for more information).'),
('PA166121251','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for mercaptopurine (Xaluprine) states that starting or target doses should be lower in patients with reduced or absent TPMT enzyme activity, and that patients with mutated NUDT15 gene also generally require a dose reduction.'),
('PA166121252','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for ofatumumab (Arzerra) contains information regarding its mechanism of action by targeting CD20 (expressed by the MS4A1 gene).'),
('PA166121326','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for pazopanib (Votrient) states that patients who carry the HLA-B*57:01 allele have an increased risk of pazopanib-associated ALT elevations.'),
('PA166121327','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for pegloticase (Krystexxa) states that screening in patients at higher risk for G6PD deficiency should be carried out prior to pegloticase treatment. It is contraindicated in these patients due to a higher risk of hemolysis and methemoglobinemia. Please note that as of June 2016 pegloticase (Krystexxa) has been withdrawn from use in the European Union.'),
('PA166122066','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for pertuzumab (Perjeta) states that it is indicated for HER2-positive early or metastatic breast cancer.'),
('PA166122067','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for ponatinib (Iclusig) states that indications of the drug include patients with Philadelphia chromosome positive (BCR-ABL1 gene fusion) acute lymphoblastic leukemia who are resistant or intolerant to dasatinib or patients who have the BCR-ABL T315I mutation, due to its mechanism of action as an inhibitor of BCR-ABL and inhibitor of mutant forms of the ABL kinase.'),
('PA166122487','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for propranolol hydrochloride (Hemangiol) gives information regarding the metabolism of the drug by three different routes which varies between individuals, but that no difference in oral clearance or elimination is observed between CYP2D6 extensive and poor metabolizers.'),
('PA166122488','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for regorafenib (Stivarga) states that the hazard ratios for overall survival and progression-free survival were lower in patients with KRAS wild-type tumors as compared to KRAS mutant tumors. However, the EPAR does not comment on the significance of this difference.'),
('PA166122546','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for rituximab (MabThera) contains information regarding one of the indications of the drug in patients with CD20-positive diffuse large V cell non-Hodgkin''s lymphoma in combination with CHOP chemotherapy regimen. The drug targets CD20 (MS4A1) expressing B cells to induce cell lysis.'),
('PA166122547','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for trastuzumab emtansine (Kadcyla) contains information regarding indication of the drug in patients with HER2-positive (encoded by the ERBB2 gene) breast cancer due to its mechanism of action, and HER2 positive status should be tested for by a validated method.'),
('PA166122548','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for velaglucerase alfa (VPRIV) states that the drug is indicated as a long-term enzyme replacement therapy for patients with type 1 Gaucher disease. Gaucher disease is caused by mutations in the GBA gene, resulting in a deficiency of the lysosomal enzyme beta-glucocerebrosidase.'),
('PA166122589','U.S. Food and Drug Administration',0,'Afutuzumab (GAZYVA; obinutuzumab) is used in combination with chlorambucil in patients with chronic lymphocytic leukemia who are previously untreated. The drug is a CD20-directed cytolytic monoclonal antibody, but there is no association with genetic variation within the coding gene, MS4A1, and therefore no mention of genetic testing in the drug label.'),
('PA166122592','U.S. Food and Drug Administration',0,'The FDA-approved drug label for simeprevir (OLYSIO) contains information regarding a genetic variant near the IFNL3 gene (IL28B, rs12979860, a C to T change) which is a strong predictor of response to peginterferon alfa and ribavirin treatment. Simeprevir must not be used as a monotherapy, and should be administered in combination with both peginterferon alfa and ribavirin for treatment of chronic hepatitis C genotype 1.'),
('PA166122594','U.S. Food and Drug Administration',0,'Sofosbuvir (SOVALDI) is indicated for the treatment of chronic hepatitis C in combination with ribavirin and/or peg-interferon alfa. The FDA-approved drug label for sofosbuvir contains information regarding a genetic variant near the IFNL3 gene (IL28B, rs12979860, a C to T change). Though the sofosbuvir label itself does not discuss why this variant is relevant, literature evidence has shown that this variant is a strong predictor of response to peginterferon alfa and ribavirin treatment.'),
('PA166122607','U.S. Food and Drug Administration',0,'Vortioxetine (BRINTELLIX) is indicated as a treatment for major depressive disorder. The FDA-approved drug label for vortioxetine notes that the maximum recommended dose in patients who are known CYP2D6 poor metabolizers is 10 mg/day.'),
('PA166122826','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for voriconazole (VFEND) does not contain pharmacogenetic information. It contains warning information regarding the co-administration of drugs that are substrates, inhibitors or activators of CYP3A4, CYP2C9 or CYP2C19 due to drug-drug interactions.'),
('PA166122907','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for vandetanib (Caprelsa) recommends testing for RET mutation status, as patients without RET mutations may have decreased benefit from vandetanib treatment.'),
('PA166122947','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for ranolazine (Ranexa) states that CYP2D6 poor metabolizers (PMs) had higher AUC as compared to extensive metabolizers (EMs), and that the risk for increased exposure leading to adverse events is higher in PMs than EMs.'),
('PA166122966','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for darifenacin (Emselex) states that a population pharmacokinetic analysis of Phase III data showed that steady-state exposure was 66% higher in CYP2D6 poor metabolizers as compared to extensive metabolizers.'),
('PA166122967','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for fesoterodine (Toviaz) states that Cmax and AUC of the active metabolite are 1.7 and 2-fold higher, respectively, in CYP2D6 poor metabolizers as compared to extensive metabolizers.'),
('PA166122968','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for silenafil (Viagra) contains genetic information regarding its contraindication in patients with hereditary degenerative retinal disorders. It also mentions that the drug is metabolized by CYP3A4 and CYP2C9, and that a lower dose of silenafil should be considered in patients taking CYP3A4 inhibitors concomitantly.'),
('PA166122969','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for vardenafil (Levitra) contains genetic information regarding its contraindication in patients with hereditary retinal degenerative disorders. It also mentions that the drug is metabolized primarily by CYP3A4 and that concomitant use of potent CYP3A4 inhibitors is contraindicated, or dose adjustments should be made when prescribed with moderate CYP3A4 inhibitors.'),
('PA166122970','U.S. Food and Drug Administration',0,'Succinylcholine (QUELICIN) is rapid acting, depolarizing skeletal muscle relaxant indicated as an adjunct to general anesthesia. The label warns that individuals who are carriers of the atypical variant of the plasma cholinesterase gene (BCHE) are at risk of prolonged apnea if administered succinylcholine. The label also notes the risk for malignant hyperthermia.'),
('PA166122971','U.S. Food and Drug Administration',0,'The FDA-approved drug label for darifenacin (ENABLEX) notes that CYP2D6 poor metabolizers may have increased maximum plasma concentrations of darifenacin, as compared to CYP2D6 extensive metabolizers. However, the label does not comment on the clinical significance of these increased concentrations.'),
('PA166122972','U.S. Food and Drug Administration',0,'The FDA-approved drug label for fesoterodine (TOVIAZ) notes that CYP2D6 poor metabolizers may have increased maximum plasma concentrations of the active metabolite of fesoterodine, as compared to CYP2D6 extensive metabolizers. However, the label does not comment on the clinical significance of these increased concentrations.'),
('PA166123048','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for cabazitaxel (Jevtana) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A, and coadministration of strong CYP3A inhibitors or inducers should be avoided.'),
('PA166123387','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for axitinib (Inlyta) states that population pharmacokinetic analyses show no clinically relevant effects of UGT1A1 or CYP2C19 genotype.'),
('PA166123388','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for ruxolitinib (Jakavi) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4 and CYP2C9, and suggests dosing adjustments and more frequent monitoring of hematology parameters if co-administered with strong CYP3A4 inhibitors or inducers, or dual inhibitors of CYP3A4 and CYP2C9.'),
('PA166123390','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for fampridine (Fampyra) does not contain pharmacogenetic information. It contains information regarding the role of OCT2 (SLC22A2) in the secretion of fampridine, and states that concomitant use of drugs that are onohibitors of OCT2 are contraindicated, and cautions the use of concomitant drugs that are substrates of OCT2.'),
('PA166123408','European Medicines Agency',1,'The EMA European Public Assessment Report (EPAR) for vortioxetine (Brintellix) states that CYP2D6 poor metabolizers have higher concentrations of vortioxetine as compared to extensive metabolizers. Additionally, for CYP2D6 ultra-rapid metabolizers, a dose adjustment may be considered depending on individual patient response.'),
('PA166123409','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for aliskiren (Rasilez HCT) does not contain pharmacogenetic information. It contains information regarding the role of ABCB1 (P-gp, MDR1) in intestinal absorption and biliary secretion of aliskiren, and concomitant use of aliskiren with potent P-gp inhibitors is contraindicated.'),
('PA166123410','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for ritonavir (Norvir) does not contain pharmacogenetic information. It contains information regarding use of ritonavir as a pharmacokinetic enhancer for certain drugs to prolong their therapeutic effects. It is a potent inhibitor of CYP3A and CYP2D6-mediated biotransformation, and the EPAR provides a list of drugs contraindicated for concomitant use with ritonavir.'),
('PA166123411','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for sirolimus (Rapamune) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4, and recommends therapeutic monitoring and dose adjustments when coadministrated with strong CYP3A inhibitors or inducers.'),
('PA166123412','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for sunitinib (SUTENT) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4, and that potent CYP3A4 inhibitors or inducers should be avoided as they may affect sunitinib plasma levels.'),
('PA166123413','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for zonisamide (Zonegran) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4, and recommends dose adjustments if CYP3A4 inducers are taken concomitantly.'),
('PA166123414','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for dronedarone (MULTAQ) states that it is a mild inhibitor of CYP2D6, and that the effect on metoprolol and propranol exposure is much below the difference seen between poor and extensive CYP2D6 metabolisers. It also contains information regarding metabolism of by dronedarone CYP3A4, and that concomitant drugs that are potent CYP3A4 inhibitors are contraindicated and potent CYP3A4 inducers are not recommended.'),
('PA166123416','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for ivabradine (Corlentor) does not contain pharmacogenetic information. It contains information regarding metabolism of ivabradine by CYP3A4, and that concomitant use of potent CYP3A4 inhibitors is contraindicated.'),
('PA166123417','European Medicines Agency',0,'Note: this medication has been withdrawn from use in the European Union.'),
('PA166123418','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for posaconazole (Noxafil) does not contain pharmacogenetic information. It contains information regarding metabolism drug-drug interactions with CYP3A4 substrates.'),
('PA166123419','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for indinavir (Crixivan) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4 and contraindicates concomitant use of drugs that are CYP3A4 substrates.'),
('PA166123420','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for fosamprenavir (Telzir) does not contain human pharmacogenetic information, but does contain pharmacogenetic information related to the genotype of the HIV virus. Concomitant use of drugs with a narrow therapeutic window that are substrates of CYP3A4 or CYP2D6 is contraindicated.'),
('PA166123421','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for atazanavir (REYATAZ) states that co-administration with voriconazole and ritonavir is not recommended, and that if voriconazole treatment is required a patient''s CYP2C19 genotype should be performed if feasible. If the patient has at least one functional CYP2C19 allele, close clinical monitoring for a loss of voriconazole and atazanvir efficacy is recommended.'),
('PA166123422','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for efavirenz, emtricitabine and tenofovir disoproxil (Atripla) states that patients with the CYP2B6*6/*6 genotype had higher Cmax as compared to patients with the CYP2B6*1/*1 genotype, and the mean QTc prolongation was 8.7 ms. The label also notes that plasma exposure may be increased in patients with the rs3745274 TT genotype (G516T).'),
('PA166123423','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for tipranavir (Aptivus) does not contain human pharmacogenetic information, but does contain pharmacogenetic information related to the genotype of the HIV virus. It contains information regarding metabolism of tipranavir by CYP3A4, and gives information regarding the coadministration of drugs that are CYP3A substrates, inhibitors or inducers.'),
('PA166123424','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for darunavir (PREZISTA) does not contain human pharmacogenetic information, but does contain pharmacogenetic information related to the genotype of the HIV virus. It contains information regarding metabolism of darunavir by CYP3A and gives information regarding the coadministration of drugs that are CYP3A substrates, inhibitors or inducers.'),
('PA166123487','U.S. Food and Drug Administration',1,'The FDA-approved drug label for eliglustat (CERDELGA) states that it is indicated for patients with Gaucher disease type 1. CYP2D6 intermediate and extensive metabolizers have a recommended dose of 84 mg twice daily, while poor metabolizers have a recommended dose of 84 mg once daily. The label notes that CYP2D6 ultra-rapid metabolizers may not achieve adequate concentrations of eliglustat to achieve a therapeutic effect.'),
('PA166123526','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for irinotecan states that it is for the treatment of refractory, inoperable pancreatic cancer and that patients should be selected for treatment based on their stage, general condition and UGT1A1 polymorphism.'),
('PA166123527','Pharmaceuticals and Medical Devices Agency, Japan',0,'Arsenic trioxide is indicated for treatment of patients with relapsed or refractory acute promyelocytic leukemia (APL). The PMDA package insert for arsenic trioxide states that patients with APL should be characterized by presence of the t(15;17) translocation or PML/RAR-alpha gene expression.'),
('PA166123528','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for atomoxetine (Strattera) states that individuals who are CYP2D6 poor metabolizers (PMs) and administered atomoxetine may have higher exposure to the drug and be at a greater risk of experiencing adverse events. The insert recommends dosing these patients with discretion.'),
('PA166123529','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for atorvastatin states that an indication for the drug is familial hypercholesterolemia, a genetically determined condition caused by mutations in the low density lipoprotein receptor gene (LDLR).'),
('PA166123530','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for azathioprine notes that individuals with certain TPMT genetic variations may be at increased risk of developing myelotoxicity. The insert also notes that this myelotoxicity could be exacerbated by co-administration of drugs that inhibit TPMT, such as aminosalicylic acid derivatives.'),
('PA166123531','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for capecitabine states that severe adverse events have occurred in patients receiving the drug who are dihydropyrimidine dehydrogenase (DPD)-deficient. DPD is the enzyme responsible for the degradation of capecitabine and other fluoropyrimidines.'),
('PA166123532','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for carbamazepine notes that the HLA-A*3101 allele appeared at a high frequency in Japanese patients who developed a serious drug rash when taking carbamazepine. The insert also notes that the HLA-B*1502 allele appeared in nearly all of a group of Han Chinese patients who developed Stevens-Johnson syndrome or toxic epidermal necrolysis when taking carbamazepine.'),
('PA166123535','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for clopidogrel states that in clinical pharmacological studies, CYP2C19 poor metabolizers had diminished inhibition of platelet aggregation.'),
('PA166123536','Pharmaceuticals and Medical Devices Agency, Japan',0,'Crizotinib is indicated for the treatment of patients with non-small cell lung cancer. The PMDA package insert for crizotinib states positive confirmation of the ALK fusion gene is necessary prior to treatment.'),
('PA166123537','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for dasatinib states that it is indicated for individuals with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).'),
('PA166123538','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for eltrombopag notes that caution should be taken when administering the drug to patients with antithrombin III (AT III; SERPINC1 gene) deficiency.'),
('PA166123539','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for fluorouracil states that severe adverse events have occurred in patients receiving the drug who are dihydropyrimidine dehydrogenase (DPD)-deficient. DPD is the enzyme responsible for the degradation of fluorouracil and other fluoropyrimidines.'),
('PA166123540','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for fulvestrant states that it is indicated for postmenopausal women with hormone-receptor positive breast cancer, and that fulvestrant should not be used in women negative for hormone receptor.'),
('PA166123541','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for gefitinib (Iressa) states that patients should be tested for EGFR gene mutations prior to administration. It also discusses the role of CYP2D6 is the metabolism of gefitinib.'),
('PA166123542','Pharmaceuticals and Medical Devices Agency, Japan',0,'Imatinib is an inhibitor of the BCR-ABL tyrosine kinase that is created by the Philadelphia chromosome rearrangement. The PMDA package insert for imatinib (Glivec) contains pharmacogenetic information regarding the indication of the drug in patients with Philadelphia chromosome positive (BCR-ABL) acute lymphoblastic leukemia.'),
('PA166123543','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for indacaterol (Onbrez) states that individuals who have low UGT1A1 expression have increased steady-state area under the concentration-time curve (AUC) and maximum plasma concentration (Cmax) as compared to UGT1A1 wild-type individuals.'),
('PA166123544','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for lapatinib states that it is indicated for individuals with breast cancer whose tumors overexpress HER2. It also contains information about the risk of severe liver injury in patients with the HLA-DQA1*02:01 or HLA-DRB1*07:01 variants.'),
('PA166123545','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for lenalidomide (Revlimid) states that it is indicated for individuals with myelodysplastic syndromes associated with a deletion of chromosome 5q.'),
('PA166123546','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for mycophenolic acid notes that caution should be used in patients with deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndromes, due to the risk for exacerbation of hyperuricemia.'),
('PA166123547','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for panitumumab (Vectibix) states that it is indicated for patients with wild-type KRAS colorectal cancer, and that patients should be selected based on RAS (KRAS and NRAS) mutation status.'),
('PA166123548','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for rasburicase notes that foreign clinical studies have shown that patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency can have severe hemolytic reactions when administered rasburicase, and patients should be carefully screened for a family history of G6PD deficiency or other red blood cell enzyme defects.'),
('PA166123549','Pharmaceuticals and Medical Devices Agency, Japan',0,'Tolterodine is metabolized by CYP2D6 into the pharmacologically active and equipotent 5-hydroxymethyl metabolite (DD01). The PMDA package insert for tolterodine (Detrusitol) notes that CYP2D6 poor metabolizers have negligible concentrations of the 5-hydroxymethyl metabolite and significantly increased concentrations of tolterodine, as compared to extensive metabolizers.'),
('PA166123550','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for trastuzumab states that it is indicated for patients with HER2-overexpressing breast or gastric cancers.'),
('PA166123551','Pharmaceuticals and Medical Devices Agency, Japan',0,'Tretinoin is indicated for the treatment of acute promyelocytic leukemia (APL). The PMDA package insert for tretinoin (VESANOID) notes that it acts on the PML-RAR-&alpha; fusion gene, allowing immature promyelocytes to differentiate into normal mature blood cells.'),
('PA166123552','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for valproic acid states that it is contraindicated in patients with known urea cycle disorders (UCDs), due to a risk for severe hyperammonemia. UCDs result from mutations in one of several genes, including ornithine transcarbamylase (OTC) deficiency and carbamoyl-phosphate synthetase 1 (CPS1) deficiency.'),
('PA166123553','Pharmaceuticals and Medical Devices Agency, Japan',0,'The HLA-B*57:01 allele is associated with a high risk of experiencing a hypersensitivity reaction to abacavir in multiple populations, including Caucasians and African-Americans. However, the PMDA package insert for abacavir notes that the association between HLA-B*57:01 and risk of an abacavir hypersensitivity reaction is unknown in Japanese patients, and that the *57:01 allele has a reported prevalence of only 0.1% in the Japanese population.'),
('PA166124617','U.S. Food and Drug Administration',0,'The FDA-approved drug label for ceritinib (ZYKADIA) states that it is indicated for patients with metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.'),
('PA166127627','Health Canada Santé Canada',0,'The product monograph for abacavir (ZIAGEN) states that all patients should be screened for the HLA-B*5701 allele prior to initiating or re-initiating treatment with abacavir, due to the high risk of experiencing a hypersensitivity reaction (HSR) for patients carrying this allele.'),
('PA166127628','Health Canada Santé Canada',0,'The product monographs for tramadol and acetaminophen (APO-TRAMADOL/ACET) and tramadol (APO-TRAMADOL) note that patients who are CYP2D6 poor metabolizers may have increased tramadol concentrations as compared to those who are CYP2D6 extensive metabolizers.'),
('PA166127629','Health Canada Santé Canada',0,'The product monograph for afatinib (GIOTRIF) states that it is indicated for the treatment of patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s), including exon 19 deletions and the exon 21 L858R point mutation. A validated test is required to identify EGFR mutation status.'),
('PA166127630','Health Canada Santé Canada',0,'The product monograph for anastrozole states that it is indicated for treatment of postmenopausal women with hormone receptor positive advanced breast cancer.'),
('PA166127631','Health Canada Santé Canada',0,'The product monograph for aripiprazole (ABILIFY) notes that CYP2D6 poor metabolizers have approximately an 80% increase in aripiprazole exposure and approximately a 30% decrease in exposure to the active metabolite compared to CYP2D6 extensive metabolizers.'),
('PA166127632','Health Canada Santé Canada',0,'The product monograph for arsenic trioxide (TRISENOX) states that is indicated for patients with acute promyelotic leukemia (APL) characterized by the presence of the t(15;17) translocation or promyelocytic leukemia-retinoic-acid-receptor alpha (PML-RARa) gene expression.'),
('PA166127633','Health Canada Santé Canada',0,'The product monograph for atomoxetine notes that CYP2D6 poor metabolizers (PMs) have a 10-fold higher area under the curve (AUC) and a 5-fold higher peak concentration of the drug as compared to extensive metabolizers (EM); this leads to a higher rate of some adverse events for PMs compared to EMs.'),
('PA166127634','Health Canada Santé Canada',0,'The product monograph for atorvastatin states that it is indicated for hyperlipidemic and dyslipidemic conditions, including homozygous and heterozygous familial hypercholesterolemia, genetically determined conditions caused by mutations in the low density lipoprotein receptor (LDLR)'),
('PA166127635','Health Canada Santé Canada',0,'The product monograph for azathioprine notes that individuals with an inherited deficiency of the thiopurine methyltransferase (TPMT) enzyme may be at risk for developing myelosuppression when treated with the drug.'),
('PA166127640','Health Canada Santé Canada',0,'The product monograph for boceprevir (VICTRELIS) contains information regarding a genetic variant near the IFNL3 gene (IL28B, rs12979860, a C to T change) which is a strong predictor of response to peginterferon alfa-2b/ribavirin treatment.'),
('PA166127641','Health Canada Santé Canada',0,'The product monograph for bosutinib (BOSULIF) states that it is indicated for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia.'),
('PA166127644','Health Canada Santé Canada',0,'The product monograph for capecitabine states that it is contraindicated in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency. However, genetic testing or screening for DPD deficiency is not mentioned.'),
('PA166127645','Health Canada Santé Canada',0,'The product monograph for carbamazepine states that the individuals with the HLA-A*31:01 and HLA-B*15:02 alleles are at risk of developing serious cutaneous adverse drug reactions when receiving the drug, and it is recommended that physicians consider HLA-A*31:01 and HLA-B*15:02 genotyping as a screening tool in genetically at-risk populations.'),
('PA166127646','Health Canada Santé Canada',0,'The product monograph for carvedilol notes that CYP2D6 poor metabolizers exhibit 2- to 3-fold higher plasma concentrations of R( + )-carvedilol compared to extensive metabolizers. Plasma levels of S( - )-carvedilol are increased only about 20 - 25% in poor metabolizers.'),
('PA166127647','Health Canada Santé Canada',0,'The product monograph for celecoxib (CELEBREX) notes that patients who are CYP2C9 poor metabolizers should be administered celecoxib with caution. It further states that the drug should be introduced at half the lowest recommended dose in these individuals, with a maximum recommended dose of 100 mg/day. However, the product monograph does not discuss CYP2C9 genotyping prior to treatment.'),
('PA166127648','Health Canada Santé Canada',0,'The product monograph for cetuximab (ERBITUX) states that it is indicated for treatment of EGFR-expressing K-ras wild-type metastatic colorectal carcinoma.'),
('PA166127649','Health Canada Santé Canada',0,'The product monograph for chlorpropamide notes that caution should be used in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency due to the risk for hemolytic anemia, and that a non-sulfonylurea alternative should be considered in this subset of patients. G6PD deficiency is a condition caused by variants in the G6PD gene which can be determined by enzymatic or genetic tests, however the drug label does not specifically mention testing.'),
('PA166127650','Health Canada Santé Canada',0,'The product monograph for citalopram recommends that patients who are CYP2C19 poor metabolizers receive an initial dose of 10 mg daily during the first two weeks of treatment, and should not receive a dose of greater than 20 mg/day. However, it makes no statements regarding genetic testing of CYP2C19 prior to treatment.'),
('PA166127653','Health Canada Santé Canada',0,'The product monograph for clopidogrel (PLAVIX) states that CYP2C19 poor metabolizers may be at increased risk for experiencing cardiovascular events when taking the drug at recommended doses as compared to normal CYP2C19 metabolizers, and that an alternative treatment or treatment strategies should be considered in these patients.'),
('PA166127654','Health Canada Santé Canada',0,'CYP2D6 ultra-rapid metabolizers may experience overdose symptoms such as extreme sleepiness, confusion, or shallow breathing at normal dosing regimens of codeine. Mothers who are ultra-rapid metabolizers and breast-feeding have higher-than-expected levels of morphine in breast milk and potentially dangerously high serum morphine levels in their breastfed infants.'),
('PA166127655','Health Canada Santé Canada',0,'The product monograph for crizotinib (XALKORI) states that it is indicated for patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer.'),
('PA166127656','Health Canada Santé Canada',0,'The product monograph for dabrafenib (TAFINLAR) states that it is indicated for treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.'),
('PA166127657','Health Canada Santé Canada',0,'The product monograph for dapsone (ACZONE) notes that oral dapsone treatment can result in hemolysis and hemolytic anemia, particularly in patients who are glucose-6-phosphate dehydrogenase (G6PD)-deficient. However, for this topical formulation of the drug, a study showed no clinically relevant cases of hemolysis or anemia in G6PD-deficient individuals.'),
('PA166127659','Health Canada Santé Canada',0,'The product monograph for darifenacin notes that CYP2D6 poor metabolizers may have higher levels of the drug as compared to extensive metabolizers. However, it also notes that there are no special dosing requirements for poor metabolizers.'),
('PA166127660','Health Canada Santé Canada',0,'The product monograph for dasatinib (SPRYCEL) states that it is indicated for the treatment of adults with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia.'),
('PA166127661','Health Canada Santé Canada',0,'The product monograph for dexlansoprazole (DEXILANT) notes that CYP2C19 intermediate and poor metabolizers generally have higher exposure to the drug as compared to extensive metabolizers.'),
('PA166127662','U.S. Food and Drug Administration',0,'The FDA-approved label for arformoterol (BROVANA) states those with reduced CYP2D6 and/or UGT1A1 activity do not show changes in their systemic exposure to the drug compared to those with normal CYP2D6 and/or UGT1A1 enzymatic activities.'),
('PA166127663','U.S. Food and Drug Administration',0,'The FDA-approved drug label for divalproex states that it is contraindicated in individuals with known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG), and suspected POLG-related disorders in children under 2 years old.'),
('PA166127664','U.S. Food and Drug Administration',0,'Ibrutinib (IMBRUVICA) is a kinase inhibitor indicated for patients with multiple different cancer types, including those with chronic lymphocytic leukemia with 17p deletion. The label also notes the presence of individuals with 11q deletion in clinical studies.'),
('PA166127665','Health Canada Santé Canada',0,'The product monograph for divalproex states that it is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG), and in children under two years of age who are suspected of having a POLG-related disorder.'),
('PA166127666','Health Canada Santé Canada',0,'The product monograph for drospirenone and ethinyl estradiol (YAZ) states that the drug is contraindicated in women with Factor V Leiden mutation, antithrombin-III-deficiency, protein C deficiency and protein S deficiency (among other contraindications), due to the risk for arterial or venous thrombosis.'),
('PA166127667','Health Canada Santé Canada',0,'The product monograph for efavirenz, emtricitabine and tenofovir (ATRIPLA) states that patients homozygous for the G516T genetic variant in CYP2B6 may have increased plasma exposure of the drug. However, the effect of this increase on the occurrence of adverse events is unclear.'),
('PA166127668','Health Canada Santé Canada',0,'The product monograph for eltrombopag (REVOLADE) states that caution should be used when administering the drug to patients with risk factors for thromboembolism, such as Factor V Leiden mutation (rs6025 in F5) and antithrombin III deficiency (SERPINC1).'),
('PA166127669','Health Canada Santé Canada',0,'The product monograph for erlotinib (TARCEVA) states that it is indicated for patients with non-small cell lung cancer (NSCLC) who have a confirmed activating EGFR mutation.'),
('PA166127670','Health Canada Santé Canada',0,'The product monograph for esomeprazole states that CYP2C19 poor metabolizers have increased concentrations of the drug as compared to the rest of the population, but that dosage adjustment based on CYP2C19 genotype is not necessary.'),
('PA166127671','Health Canada Santé Canada',0,'The product monograph for everolimus (AFINITOR) states that it is indicated for treatment of hormone receptor-positive, HER2-negative breast cancer.'),
('PA166127672','Health Canada Santé Canada',0,'The product monograph for exemestane states that it is indicated for the treatment of estrogen receptor-positive early breast cancer.'),
('PA166127673','Health Canada Santé Canada',0,'The product monograph for fesoterodine (TOVIAZ) states that CYP2D6 poor metabolizers have increased levels of the active metabolite of the drug as compared to extensive metabolizers. However, it makes no statements regarding genetic testing of CYP2D6.'),
('PA166127674','Health Canada Santé Canada',0,'The product monograph for fluorouracil states that it should be used with care in patients who have a dihydropyrimidine dehydrogenase (DYPD) deficiency, due to the risk for experiencing toxicity.'),
('PA166127675','Health Canada Santé Canada',0,'The product monograph for galantamine notes that CYP2D6 poor metabolizers have decreased clearance and increased AUC of galantamine as compared to extensive metabolizers. However, it also states that dosage adjustment based on CYP2D6 genotype is not necessary since the drug is individually titrated to tolerability.'),
('PA166127676','Health Canada Santé Canada',0,'The product monograph for gefitinib (IRESSA) states that it is indicated for patients with activating EGFR mutations, and should not be used in those with EGFR mutation negative tumors.'),
('PA166127677','Health Canada Santé Canada',0,'Glibenclamide (glyburide; GLYBE) belongs to a class of drugs known as sulfonylurea agents. The product monograph for glibenclamide states that caution should be used when administering this drug to patients with G6PD deficiency due to the risk for hemolytic anemia, and that a nonsulfonylurea agent should be considered in these individuals.'),
('PA166127678','Health Canada Santé Canada',0,'Glimepiride (AMARYL) belongs to a class of drugs known as sulfonylurea agents. The product monograph for glimepiride states that caution should be used when administering this drug to patients with G6PD deficiency due to the risk for hemolytic anemia, and that a nonsulfonylurea agent should be considered in these individuals.'),
('PA166127681','Health Canada Santé Canada',0,'The product monograph for ibrutinib (IMBRUVICA) states that it is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL), including those with the 17p deletion.'),
('PA166127682','Health Canada Santé Canada',0,'The product monograph for imatinib (GLEEVEC) contains pharmacogenetic information regarding the indication of the drug in patients with tumors positive for biomarkers including Kit (CD117), BCR-ABL1 (Philadelphia chromosome), PDGFR and FIP1L1-PDGFRalpha rearrangements.'),
('PA166127683','Health Canada Santé Canada',0,'The product monograph for irinotecan (CAMPTOSAR) notes that a reduced irinotecan starting dose should be considered in individuals homozygous for the UGT1A1*28 (rs8175347) allele, due to the risk for hematologic toxicity.'),
('PA166127684','Health Canada Santé Canada',0,'Ivacaftor (KALYDECO) is indicated in cystic fibrosis patients 6 years and older who have one of the following variants in CFTR: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R or G970R, or in patients 18 years and older with the R117H variant. The product monograph also states that ivacaftor is not effective in patients homozygous for the F508del variant.'),
('PA166127685','Health Canada Santé Canada',0,'The product monograph for lapatinib (TYKERB) states that it is indicated for patients with metastatic breast cancer whose tumours overexpress HER2. It also notes that those with the HLA-DQA1*02:01 and HLA-DRB1*07:01 alleles have an increased risk of lapatinib-associated hepatotoxicity. The product monograph does not comment on genotyping for the HLA alleles.'),
('PA166127686','Health Canada Santé Canada',0,'The product monograph for lenalidomide (REVLIMID) states that it is indicated for individuals with myelodysplastic syndromes associated with a deletion of chromosome 5q.'),
('PA166127687','Health Canada Santé Canada',0,'The product monograph for letrozole (FEMARA) states that it is indicated for the treatment of hormone-receptor positive early breast cancer.'),
('PA166127688','Health Canada Santé Canada',0,'Lomitapide (JUXTAPID) is indicated as an adjunct to a low-fat diet and other lipid lowering treatments in patients with homozygous familial hypercholesterolemia (HoFH). Mutations in the LDL receptor gene (LDLR) are the most common cause of HoFH, however, mutations in other genes (such as APOB) can also lead to HoFH.'),
('PA166127690','Health Canada Santé Canada',0,'The product monograph for mercaptopurine (PURINETHOL) states that individuals who are TPMT deficient are at risk of developing life-threatening bone marrow suppression when receiving the drug, and that substantial dose reductions are usually required for these individuals.'),
('PA166127691','Health Canada Santé Canada',0,'The product monograph for metoprolol notes that CYP2D6 poor metabolizers exhibit higher plasma concentrations of the drug as compared to extensive metabolizers, however these differences in plasma concentrations seem to have little to no effect on safety or tolerability.'),
('PA166127692','Health Canada Santé Canada',0,'The product monograph for mycophenolic acid (MYFORTIC) states that it should be avoid in patients with hereditary deficiencies of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT, encoded by HPRT1), such as Lesch-Nyhan and Kelley-Seegmiller syndrome.'),
('PA166127693','Health Canada Santé Canada',0,'The product monograph for nilotinib (TASIGNA) states that it is indicated for patients with Philadelphia chromosome positive (BCR-ABL1 fusion) chronic myeloid leukemia, though individuals with the BCR-ABL T315I mutation are highly resistant to the drug. The monograph also notes that patients homozygous for the UGT1A1*28 allele (rs8175347; (TA)7) may be at risk for hyperbilirubinemia when receiving nilotinib.'),
('PA166127694','Health Canada Santé Canada',0,'The product monograph for nitrofurantoin states that individuals with a glucose-6-phosphate dehydrogenase (G6PD) deficiency may be at risk for hemolytic anemia when receiving the drug, and that it should be discontinued if the patient exhibits signs of hemolysis.'),
('PA166127695','Health Canada Santé Canada',0,'The product monograph for norelgestromin and ethinyl estradiol (EVRA) states that the drug is contraindicated in women with Factor V Leiden mutation, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinaemia due to mutations in the MTHFR gene and prothrombin mutation G20210A (among other contraindications), due to the risk for arterial or venous thrombosis.'),
('PA166127696','Health Canada Santé Canada',0,'The product monograph for norfloxacin states that hemolytic reactions have occurred in patients with glucose-6-phosphate dehydrogenase deficiency.'),
('PA166127697','Health Canada Santé Canada',0,'The product monograph for nortriptyline notes that individuals who are CYP2D6 poor metabolizers may have higher than expected levels of tricyclic antidepressants (of which nortriptyline is a member) when given usual doses.'),
('PA166127698','Health Canada Santé Canada',0,'The product monograph for omeprazole (LOSEC) states that CYP2C19 poor metabolizers have higher plasma concentrations of the drug as compared to extensive metabolizers. However, the monograph also notes that this has no implication on dosing of omeprazole.'),
('PA166127699','Health Canada Santé Canada',0,'The product monograph for panitumumab (VECTIBIX) states that it is indicated for patients with EGFR-expressing metastatic colorectal carcinoma (mCRC) with wild-type KRAS, and should not be used in patients with KRAS-mutant mCRC or for whom KRAS mutation status is unknown.'),
('PA166127700','Health Canada Santé Canada',0,'The product monograph for pertuzumab (PERJETA) states that it is indicated in combination with trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer.'),
('PA166127701','Health Canada Santé Canada',0,'The product monograph for phenytoin (DILANTIN) notes that individuals with the HLA-B*1502 allele have an increased risk of developing Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) when receiving the drug. It further notes that this allele is common in individuals of Asian ancestry, and HLA-B genotyping should be considered as a screening tool in these patients.'),
('PA166127702','Health Canada Santé Canada',0,'The product monograph for primaquine states that caution should be used in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency or NADH methemoglobin reductase (CYB5R1-4) deficiency due to the risk of hemolytic anemia and methemoglobinemia, respectively.'),
('PA166127704','Health Canada Santé Canada',0,'The product monograph for propafenone notes that individuals with reduced CYP2D6 activity may have higher plasma concentrations of the drug as compared to those who do not have reduced CYP2D6 activity.'),
('PA166127705','Health Canada Santé Canada',0,'The product monograph for quinine states that it is contraindicated in patients with G6PD deficiency. However, it makes no statements regarding testing for G6PD deficiency prior to treatment.'),
('PA166127706','Health Canada Santé Canada',0,'The product monograph for rabeprazole states that individuals with CYP2C19 deficiency have reduced metabolism of rabeprazole.'),
('PA166127707','Health Canada Santé Canada',0,'The product monograph for rasburicase (FASTURTEC) states that patients at higher risk for G6PD deficiency (e.g. those of African or Mediterranean ancestry) be screened prior to starting treatment, due to the risk of severe hemolytic anemia.'),
('PA166127708','Health Canada Santé Canada',0,'The product monograph for risperidone notes that since CYP2D6 is responsible for the metabolism of risperidone to 9-hydroxyrisperidone, the levels of each differ between CYP2D6 poor and extensive metabolizers. However, the concentration of risperidone and 9-hydroxyrisperidone combined does not differ substantially between poor and extensive metabolizers.'),
('PA166127709','Health Canada Santé Canada',0,'The product monograph for rosuvastatin states that it is indicated for hyperlipidemic and dyslipidemic conditions, including homozygous familial hypercholesterolemia, a genetically determined condition caused by mutations in the low density lipoprotein receptor (LDLR)'),
('PA166127710','Health Canada Santé Canada',0,'The product monograph for simeprevir (GALEXOS) contains information regarding a genetic variant near the IFNL3 gene (IL28B, rs12979860) which is a strong predictor of response to peginterferon alfa (PegIFN-alfa) and ribavirin (RBV) treatment. Simeprevir is only indicated in combination with PegIFN-alfa and RBV, it is not indicated as a monotherapy.'),
('PA166127712','Health Canada Santé Canada',0,'The product monograph for sodium phenylbutyrate (Pheburane) states that it is indicated for treatment of urea cycle disorders due to deficiencies of carbamylphosphate synthetase (CPS1), ornithine transcarbamylase (OTC) or argininosuccinate synthetase (ASS1).'),
('PA166127713','Health Canada Santé Canada',0,'The product monograph for succinylcholine notes that it should be used with caution, if at all, in patients know or suspected of being homozygous for the atypical plasma cholinesterase gene (BCHE), due to the risk for prolonged muscle paralysis.'),
('PA166127714','Health Canada Santé Canada',0,'The product monograph for sulfadiazine states that it should be used in caution in patients who are deficient for glucose-6-phosphate dehydrogenase (G6PD) due to the risk for hemolysis. However, the monograph makes no mention of testing for G6PD deficiency prior to treatment.'),
('PA166127715','Health Canada Santé Canada',0,'The product monograph for sulfamethoxazole and trimethoprim (SULFATRIM) states that hemolysis may occur in individuals taking the drug who are deficient in glucose-6-phosphate dehydrogenase (G6PD). However, it does not make any statements regarding testing for G6PD deficiency prior to treatment.'),
('PA166127716','Health Canada Santé Canada',0,'The product monograph for sulfasalazine (SALAZOPYRIN) notes that patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency should be closely monitored for signs of hemolytic anemia when receiving the drug. However, no statement is made regarding testing for G6PD deficiency prior to treatment.'),
('PA166127717','Health Canada Santé Canada',0,'The product monograph for erythromycin and sulfisoxazole states that it is contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, due to the risk for hemolysis. However, the monograph does not discuss testing for G6PD deficiency prior to treatment.'),
('PA166127718','Health Canada Santé Canada',0,'The product monograph for tamoxifen states that it is indicated for treatment of early breast cancer in women with estrogen receptor positive tumors. It also notes that individuals with low CYP2D6 activity (or using CYP2D6 inhibitors) may have reductions in plasma concentrations of the active metabolite of tamoxifen.'),
('PA166127719','Health Canada Santé Canada',0,'The product monograph for tetrabenazine notes that the tetrabenazine active metabolite HTBZ is likely increased in CYP2D6 poor metabolizers as compared to extensive metabolizers, and that caution in dosing should be exercised.'),
('PA166127720','Health Canada Santé Canada',0,'The product monograph for thioguanine (LANVIS) notes that individuals with deficiency of the thiopurine methyltransferase (TPMT) enzyme may be at increased risk of developing myelosuppression when receiving the drug, and that testing for TPMT deficiency is available.'),
('PA166127721','Health Canada Santé Canada',0,'The product monograph for tolterodine notes that CYP2D6 is responsible for the metabolism of tolterodine to its active metabolite DD 01. However, since tolterodine and DD 01 have similar pharmacological effects, the net activity of tolterodine is expected to be similar regardless of CYP2D6 metabolizer status.'),
('PA166127722','Health Canada Santé Canada',0,'The product monograph for trametinib (MEKINIST) states that it is indicated for patients with unresectable or metastatic melanoma with a BRAF V600 mutation.'),
('PA166127723','Health Canada Santé Canada',0,'The product monograph for trastuzumab emtansine (KADCYLA) states that it is indicated for patients with HER2-positive, metastatic breast cancer who received prior treatment with trastuzumab and a taxane, separately or in combination.'),
('PA166127724','Health Canada Santé Canada',0,'The product monograph for trastuzumab (HERCEPTIN) states that it is indicated for patients with early or metastatic breast cancer, or metastatic adenocarcinoma of the stomach or gastroesophageal junction, whose tumors are HER2 positive.'),
('PA166127725','Health Canada Santé Canada',0,'Tretinoin (VESANOID) is a derivative of vitamin A (retinol) used for the treatment of skin conditions and acute promyelocytic leukemia (APL). APL is characterized by the translocation t(15;17) and PML/RAR alpha (RARA) fusion protein.'),
('PA166127726','Health Canada Santé Canada',0,'The product monograph for valproic acid states that it is contraindicated in patients with mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG) or in patients with known urea cycle disorders, particularly ornithine transcarbamylase (OTC) deficiency.'),
('PA166127727','Health Canada Santé Canada',0,'The product monograph for velaglucerase alfa (VPRIV) states that it is indicated for the treatment of type 1 Gaucher disease. Gaucher disease is caused by mutations in the GBA gene, resulting in a deficiency of the enzyme beta-glucocerebrosidase. Velaglucerase alfa is an enzyme replacement therapy.'),
('PA166127728','Health Canada Santé Canada',0,'The product monograph for vemurafenib (ZELBORAF) states that it is indicated for the treatment of patients with BRAF V600 mutation-positive melanoma, and that it should not be used in patients with BRAF wild-type melanoma.'),
('PA166127729','Health Canada Santé Canada',0,'MoviPrep, a solution containing Vitamin C, is a laxative used for colon cleansing in preparation for a colonoscopy. Because it contains Vitamin C (ascorbic acid), the label warns that hemolytic reactions are possible in those with G6PD deficiency.'),
('PA166127730','Health Canada Santé Canada',0,'The product monograph for voriconazole notes that CYP2C19 poor metabolizers have, on average, 4-fold higher exposure to the drug as compared to extensive metabolizers. However, the product monograph does not make any statements regarding genetic testing of CYP2C19 prior to treatment.'),
('PA166127731','Health Canada Santé Canada',0,'The product monograph for vortioxetine (TRINTELLIX) states that the concentration of the drug is approximately 2 times higher in CYP2D6 poor metabolizers as compared to extensive metabolizers.'),
('PA166127732','Health Canada Santé Canada',0,'The product monograph for warfarin (COUMADIN) notes that patients carrying one or two copies of the CYP2C9*2 or *3 alleles may require a decreased mean daily warfarin dose, and have an increased bleeding risk, as compared to those homozygous for the CYP2C9*1 allele. Additionally, variations in the VKORC1 gene, such as -1639G&gt;A, are also associated with changes in the dose requirement of warfarin.'),
('PA166129447','European Medicines Agency',1,'The EMA European Public Assessment Report (EPAR) for eliglustat (Cerdelga) states that it is indicated for adults with Gaucher disease type 1. CYP2D6 intermediate and extensive metabolizers have a recommended dose of 84 mg twice daily, while poor metabolizers have a recommended dose of 84 mg once daily. The label notes that eliglustat should not be used in patients who are CYP2D6 ultra-rapid metabolizers or indeterminate metabolizers.'),
('PA166129448','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for ibrutinib (IMBRUVICA) states that is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL), including those with the 17p deletion.'),
('PA166129449','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for ceritinib (Zykadia) states that it is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), including those previously treated with crizotinib.'),
('PA166129450','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for trametinib (Mekinist) states that it is indicated for the treatment of unresectable or metastatic melanoma with a BRAF V600 mutation, Stage III melanoma with a BRAF V600 mutation following complete resection, or advanced non-small cell lung cancer with a BRAF V600 mutation.'),
('PA166129515','U.S. Food and Drug Administration',0,'Desflurane (SUPRANE) is a potent (volatile) inhalational anesthetic used to induce or maintain general anesthesia. The FDA-approved label warns that individuals with a genetic predisposition to malignant hyperthermia, or patients with Duchenne Muscular Dystrophy, are at greater risk of developing malignant hyperthermia, or hyperkaelemia, respectively, if administered desflurane.'),
('PA166129516','Health Canada Santé Canada',0,'Desflurane is a potent (volatile) inhalational anesthetic used to induce or maintain general anesthesia.'),
('PA166129517','U.S. Food and Drug Administration',0,'The FDA-approved drug label for isoflurane (FORANE) warns that individuals with a genetic predisposition to malignant hyperthermia, or patients with Duchenne Muscular Dystrophy, are at greater risk of developing malignant hyperthermia, or hyperkaelemia, respectively, if administered isoflurane.'),
('PA166129518','Health Canada Santé Canada',0,'Isoflurane is a potent (volatile) inhalational anesthetic used to induce or maintain general anesthesia.'),
('PA166129519','U.S. Food and Drug Administration',0,'The FDA-approved drug label for sevoflurane (ULTANE) states that it should not be used in patients with known or suspected susceptibility to malignant hyperthermia. Specific variants in the RYR1 and CACNA1S genes are associated with risk of malignant hyperthermia in individuals administered potent inhalational anesthetics, including sevoflurane. The label does not mention genetic testing.'),
('PA166129520','Health Canada Santé Canada',0,'Sevoflurane is a potent (volatile) inhalational anesthetic used to induce or maintain general anesthesia.'),
('PA166129525','Health Canada Santé Canada',0,'Carglumic acid (Carbaglu) indicated for patients for the treatment of acute or chronic hyperammonemia due to deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS).'),
('PA166129526','Health Canada Santé Canada',0,'Ceritinib (ZYKADIA) is indicated as a monotherapy for patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer who have progressed on or were intolerant to crizotinib.'),
('PA166129527','Health Canada Santé Canada',0,'Ponatinib (ICLUSIG) is indicated for adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), including CML or Ph+ ALL that is T315I mutation positive. The majority of patients with CML are positive for the Philadelphia chromosome (BCR-ABL1 gene fusion). The T315I mutation is known to cause resistance to other BCR-ABL kinase inhibitors.'),
('PA166129528','Health Canada Santé Canada',0,'Sodium nitrite is indicated for sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning judged to be life-threatening. Patients with G6PD deficiency are at increased risk for hemolytic crisis when administered sodium nitrite; the product monograph notes that alternative therapeutic approaches should be considered in these patients. G6PD deficiency is a condition caused by variants in the G6PD gene which can be determined by enzymatic or genetic tests. However, the drug label does not specifically mention testing'),
('PA166129553','U.S. Food and Drug Administration',1,'The FDA-approved drug label for belinostat (BELEODAQ) states that the starting dose should be reduced to 750 mg/m2 in patients known to be homozygous for the UGT1A1*28 allele to minimize dose limiting toxicities. However, testing or screening for the *28 allele is not mentioned.'),
('PA166131627','U.S. Food and Drug Administration',0,'The FDA-approved drug label for osimertinib (TAGRISSO) states that it is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, or those who have EGFR T790M mutations and whose disease has progressed on or after EGFR TKI therapy.'),
('PA166151853','U.S. Food and Drug Administration',0,'Nilotinib (Tasigna) is indicated for use in patients diagnosed with Philadelphia chromosome positive (presence of a BCR-ABL1 gene fusion) chronic myeloid leukemia, due to its mechanism of action. Individuals with the UGT1A1*28 genotype (TA)7/(TA)7 (rs8175347) are at an increased risk of hyperbilirubinemia when taking nilotinib.'),
('PA166151878','U.S. Food and Drug Administration',0,'Lapatinib (TYKERB) is indicated for patients with breast cancer whose tumors overexpress HER2 (ERBB2). The FDA-approved drug label for lapatinib notes that the HLA-DQA1*02:01 and HLA-DRB1*07:01 alleles have been associated with hepatotoxicity in individuals received the drug, but does not discuss genetic testing for these alleles.'),
('PA166151881','U.S. Food and Drug Administration',0,'The FDA-approved drug label for rasburicase (Elitek) states that patients at higher risk for G6PD deficiency, such as those of African or Mediterranean ancestry, should be screened prior to starting treatment, as rasburicase is contraindicated in patients with G6PD deficiency. The label also states that It is unclear whether patients with NADH cytochrome b5 reductase (CYB5R1, 2, 3, 4) deficiency are at risk for methemoglobinemia or hemolytic anemia.'),
('PA166151882','U.S. Food and Drug Administration',0,'The FDA-approved label for carbamazepine (TEGRETOL) states that a moderate association has been found between HLA-A*3101 and the risk of developing hypersensitivity reactions to carbamazepine, though it does not mention testing for this allele. However, the label does state that screening of patients with ancestry in genetically at-risk populations (patients of Asian descent) for the presence of the HLA-B*1502 allele should be carried out prior to treatment due to a high risk of serious and something fatal dermatologic reactions.'),
('PA166151974','Health Canada Santé Canada',0,'The product monograph for nilotinib (TASIGNA) notes that patients homozygous for the UGT1A1*28 allele (rs8175347; (TA)7) may be at risk for hyperbilirubinemia when receiving nilotinib. This drug is indicated for patients with Philadelphia chromosome positive (BCR-ABL1 fusion) chronic myeloid leukemia, though individuals with the BCR-ABL T315I mutation are highly resistant to the drug.'),
('PA166152939','U.S. Food and Drug Administration',0,'The FDA-approved drug label for ivacaftor and lumacaftor combination (ORKAMBI) states that it is indicated for treatment of cystic fibrosis in patients age 12 years and older who are homozygous for the F508del mutation (rs113993960) in the CFTR gene.'),
('PA166153432','U.S. Food and Drug Administration',0,'The FDA-approved drug label for flibanserin (ADDYI) states that poor metabolizers of CYP2C19 had increased exposure to the drug as compared to extensive metabolizers. One subject who was a poor metabolizer experienced syncope. The label also notes the influence of CYP2D6 and CYP2C9 on flibanserin exposure.'),
('PA166153492','U.S. Food and Drug Administration',0,'The FDA-approved drug label for brivaracetam (BRIVIACT) states that CYP2C19 intermediate or poor metabolizers may have increased levels of brivaracetam, and that poor metabolizers may require a dose reduction.'),
('PA166159064','U.S. Food and Drug Administration',0,'Elosulfase alfa (VIMIZIM) is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with mucopolysaccharidosis type IVA, also known as Morquio A syndrome. This disease results from deficiency or marked reduction of the galactosamine (N-acetyl)-6-sulfatase (GALNS) enzyme.'),
('PA166159584','Health Canada Santé Canada',0,'Afutuzumab (GAZYVA; obinutuzumab) is used in combination with chlorambucil in patients with chronic lymphocytic leukemia who are previously untreated. The drug is a CD20-directed cytolytic monoclonal antibody, but there is no association with genetic variation within the coding gene, MS4A1, and therefore no mention of genetic testing in the drug label.'),
('PA166159586','Health Canada Santé Canada',0,'The HCSC product monograph for aliskiren (Rasilez HCT) does not contain pharmacogenetic information. It contains information regarding the role of ABCB1 (Pgp, MDR1) in intestinal absorption of aliskiren, and concomitant use of aliskiren with potent P-gp inhibitors is contraindicated.'),
('PA166159707','Health Canada Santé Canada',0,'The HCSC for atazanavir (Reyataz) contains pharmacogenetic information related to co-treatment with voriconazole and ritonavir: atazanavir exposure is expected to be decreased and voriconazole exposure is expected to be increased in patients who do not have a functional CYP2C19 allele.'),
('PA166159938','Health Canada Santé Canada',0,'Belimumab (BENLYSTA) is a human IgG1&lambda; monoclonal antibody, indicated for use in adults with active, autoantibody-positive, systemic lupus erythematosus who are receiving standard therapy. It acts by blocking binding of soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B-cell survival factor, to its receptors on B cells.'),
('PA166159962','U.S. Food and Drug Administration',0,'Although the alirocumab (PRALUENT) drug label does not specifically mention genetic testing, one of the indications listed is for the treatment of adults with heterozygous familial hypercholesterolemia. Familial hypercholesterolemia is commonly caused by mutations in the LDLR gene.'),
('PA166159963','U.S. Food and Drug Administration',0,'The FDA-approved drug label for blinatumomab (BLINCYTO) states that it is indicated for treatment of MRD-positive B-cell precursor acute lymphoblastic leukemia (ALL) or relapsed or refractory B-cell precursor ALL. The label notes whether patients were Philadelphia chromosome-positive or negative in the Clinical Studies section.'),
('PA166159964','U.S. Food and Drug Administration',0,'The FDA-approved drug label for olaparib (Lynparza) states that it is indicated for treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, as well as deleterious or suspected deleterious germline or somatic BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. The label also notes that patients with hormone receptor positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy.'),
('PA166160005','U.S. Food and Drug Administration',0,'The FDA-approved drug label for VIEKIRA PAK (ombitasvir, paritaprevir, ritonavir, and dasabuvir) notes the percentage of subjects in clinical studies that carried the IL28B rs12979860 non-CC genotype. However, the label does not discuss the effect of this variant or genetic testing.'),
('PA166160007','U.S. Food and Drug Administration',0,'The FDA-approved drug label for lesinurad (ZURAMPIC) states that exposure to the drug is increased in CYP2C9 poor metabolizers, and that caution should be used in these patients.'),
('PA166160009','U.S. Food and Drug Administration',0,'The FDA-approved drug label for pembrolizumab (KEYTRUDA) states that it is indicated for the treatment of patients with a variety of cancers whose tumors express PD-L1 (CD274) as detected by an FDA-approved test. Pembrolizumab is approved as first line therapy for patients with no EGFR and ALK genomic tumor aberrations and for patients with EGFR and ALK genomic tumor aberrations who have disease progression on FDA-approved therapies.'),
('PA166160010','U.S. Food and Drug Administration',0,'The FDA-approved drug label for TIVICAY (dolutegravir) states that subjects with UGT1A1 genotypes that result in poor metabolism of the drug have decreased clearance and increased AUC as compared to those who have UGT1A1 genotypes that result in normal dolutegravir metabolism. The label does not mention specific UGT1A1 variants or genetic testing.'),
('PA166160021','U.S. Food and Drug Administration',0,'The FDA-approved drug label for cabozantinib (COMETRIQ) states that RET mutation status was determined in clinical studies of the drug, and that the drug inhibits the activity of the RET protein.'),
('PA166160039','U.S. Food and Drug Administration',0,'The FDA-approved drug label for evolocumab (REPATHA) states that it is indicated for the treatment of heterozygous familial hypercholesterolemia (HeFH) or homozygous familial hypercholesterolemia (HoFH). Familial hypercholesterolemia is commonly caused by mutations in the LDLR gene.'),
('PA166160040','U.S. Food and Drug Administration',0,'The FDA-approved drug label for parathyroid hormone (NATPARA) states that it was not studied in patients with hypoparathyroidism caused by calcium-sensing receptor (CASR) mutations.'),
('PA166160046','U.S. Food and Drug Administration',0,'The FDA-approved drug label for cobimetinib (COTELLIC) states that it is indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.'),
('PA166160049','U.S. Food and Drug Administration',0,'The FDA-approved drug label for lacosamide (VIMPAT) states that plasma concentrations of the lacosamide O-desmethyl metabolite were reduced by approximately 70% in CYP2C19 poor metabolizers (PMs) as compared to extensive metabolizers (EMs), but that there are no clinically relevant differences in lacosamide pharmacokinetics between PMs and EMs.'),
('PA166160051','U.S. Food and Drug Administration',0,'The FDA-approved drug label for alectinib (ALECENSA) states that it is indicated for the treatment of patients with ALK-positive, metastatic non-small cell lung cancer who have progressed on or are intolerant to crizotinib.'),
('PA166160052','U.S. Food and Drug Administration',0,'The FDA-approved drug label for palonosetron (ALOXI) states that there is no significant difference in clinical pharmacokinetic parameters between CYP2D6 poor and extensive metabolizers.'),
('PA166160054','U.S. Food and Drug Administration',1,'The FDA-approved drug label for brexpiprazole (REXULTI) states that known CYP2D6 poor metabolizers should have their usual dosage reduced by half, and that known CYP2D6 poor metabolizers who are also taking strong/moderate CYP3A4 inhibitors should be administered a quarter of the usual dose. However, the label does not mention genetic testing.'),
('PA166160056','U.S. Food and Drug Administration',0,'The FDA-approved drug label for cholic acid (CHOLBAM) states that one of the indications of the drug is for bile acid synthesis disorders due to single enzyme defects. This includes deficiencies in the 3&beta;-HSD (HSD3B7), AKR1D1 (AKR1D1), CYP27A1 (CYP27A1), AMACR (AMACR), and CYP7A1 (CYP7A1) enzymes.'),
('PA166160061','U.S. Food and Drug Administration',0,'The FDA-approved drug label for dinutuximab (UNITUXIN) provides information on the MYCN status of patients in a clinical study of the drug.'),
('PA166160121','U.S. Food and Drug Administration',0,'The FDA-approved drug label for nivolumab (OPDIVO) previously stated that it is indicated for the treatment of patients with BRAF V600 wild-type or BRAF V600 mutation-positive unresectable or metastatic melanoma as a single agent, among other indications. The label now indicates for unresectable or metastatic melanoma and does not define by BRAF mutation, although there is discussion of BRAF in the different clinical studies. The label states use of nivolumab (OPDIVO) in patients with ALK and EGFR variants is indicated only when FDA-approved therapies for those specific variants have failed. ALK and EGFR are not currently on the FDA Biomarker list for this drug.'),
('PA166160133','U.S. Food and Drug Administration',0,'The FDA-approved drug label for palbociclib (IBRANCE) states that it is indicated for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with either an aromatase inhibitor or fulvestrant.'),
('PA166160153','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for celecoxib (Celecox) notes that individuals with the CYP2C9 *1/*3 or *3/*3 genotypes had increased AUC or Cmax of celecoxib as compared to those with the *1/*1 genotype.'),
('PA166160162','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for efavirenz (STOCRIN) notes that patients with the CYP2B6 rs3745274 TT genotype may have an increased AUC as compared to those with the GG genotype.'),
('PA166160226','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for codeine notes that CYP2D6 ultrarapid metabolizers are at increased risk of developing side effects due to high serum levels of morphine, and that they may also have higher morphine levels in breast milk.'),
('PA166160274','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for cetuximab (ERBITUX) states that it is indicated for individuals with epidermal growth factor receptor (EGFR)-positive, progressive or recurrent colorectal cancer that is refractory and inoperable. It also notes that K-Ras mutational status should be considered when selecting patients.'),
('PA166160288','Health Canada Santé Canada',0,'Brentuximab vedotin (Adcetris) is an antibody-drug conjugate (ADC) directed at TNFRSF8 (CD30), and nonclinical data suggests its anti-cancer mechanism of action is by binding to CD30-expressing cells and then releasing a small molecule that disrupts microtubules.'),
('PA166160289','Health Canada Santé Canada',0,'The Health Canada drug label for brivaracetam (BRIVIACT) states that individuals with one or two copies of CYP2C19 decreased activity alleles may have increased levels of brivaracetam.'),
('PA166160668','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for allopurinol (TEVA) notes that the HLA-B*58:01 allele was present at a high frequency in patients with Stevens-Johnson syndrome or toxic epidermal necrolysis who came from Han Chinese, Japanese or European populations.'),
('PA166160669','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for escitalopram notes that the recommended maximum dose is 10 mg in patients with genetically absent CYP2C19 activity (poor metabolizers), due to an increased risk for developing QT prolongation and other side effects from the increased plasma concentrations.'),
('PA166160672','U.S. Food and Drug Administration',0,'The FDA-approved drug label for tamsulosin (FLOMAX) states that it should be used with caution in CYP2D6 poor metabolizers, particularly at doses higher than 0.4 mg, due to the potential for a significant increase in exposure of the drug.'),
('PA166160683','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for dapsone (PROTOGEN) states that hemolysis may occur in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.'),
('PA166160709','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for eliglustat (CERDELGA) states that a patient''s CYP2D6 genotype should be established prior to treatment, and that the drug is not recommended in CYP2D6 poor or ultrarapid metabolizers, or those who CYP2D6 metabolizer status cannot be determined.'),
('PA166160710','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for erlotinib states that it is indicated for recurrent and/or advanced inoperable non-small cell lung cancer that is positive for an EGFR gene mutation and has not been previously treated with chemotherapy.'),
('PA166160711','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for everolimus (AFINITOR) states that it is indicated for patients with locally advanced or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer after failure of treatment with letrozole or anastrozole.'),
('PA166160712','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for fesoterodine (Toviaz) states that CYP2D6 poor metabolizers had increased Cmax and AUC of the active metabolite (5-HMT) as compared to extensive metabolizers.'),
('PA166160717','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for letrozole notes that CYP2A6 slow metabolizers were found to have 2-fold higher mean plasma trough concentrations as compared to extensive metabolizers.'),
('PA166160718','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for methylene blue states that patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency or NADPH reductase (BLVRB) deficiency may have exacerbation of methemoglobinemia or hemolysis following administration.'),
('PA166160719','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for nalidixic acid states that patients with G6PD deficiency are at increased risk of hemolytic anemia.'),
('PA166160720','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for omeprazole states that the slower metabolism of the drug in CYP2C19 poor metabolizers is similar to that observed with other proton-pump inhibitors.'),
('PA166160845','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for perphenazine states that individuals who are deficient in CYP2D6 may have higher serum levels of the drug.'),
('PA166160846','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for rabeprazole states that CYP2C19 and CYP3A4 are involved in the metabolism of the drug, and provides data showing that CYP2C19 poor metabolizers have increased Cmax, AUC and half-life time as compared to extensive metabolizers.'),
('PA166160847','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for sulfadiazine (GEBEN) states that hemolysis may occur in patients with G6PD deficiency.'),
('PA166160848','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for sulfamethoxazole and trimethoprim (DAIPHEN) states that hemolysis may occur in patients with G6PD deficiency.'),
('PA166160849','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for sulfasalazine (Azulfidine) states that hemolysis may occur in patients with G6PD deficiency.'),
('PA166160850','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for tetrabenazine states that CYP2D6 poor metabolizers and intermediate metabolizer are at increased risk of developing side effects due to higher levels of the active metabolite, and that caution should be used in treating these patients.'),
('PA166160851','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for vemurafenib (ZELBORAF) states that it is indicated for patients with unresectable, refractory melanoma with BRAF gene mutation.'),
('PA166160854','Pharmaceuticals and Medical Devices Agency, Japan',0,'MoviPrep, a solution containing Vitamin C, is a laxative used for colon cleansing in preparation for a colonoscopy. Because it contains Vitamin C (ascorbic acid), the PMDA package insert warns that hemolytic reactions are possible in those with G6PD deficiency.'),
('PA166160856','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for voriconazole (VFEND) notes that it is metabolized by CYP2C19 (as well as CYP2C9 and CYP3A4) and provides tables showing the difference in pharmacokinetic metrics between extensive metabolizers (EM), intermediate metabolizers (also known as heterozygous extensive metabolizers (HEM)) and poor metabolizers (PM) in adults and pediatrics.'),
('PA166161087','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for isoniazid (ISCOTIN) notes that acetylation rate of isoniazid differs between individuals, and that about 10% of Japanese are slow acetylators.'),
('PA166161219','U.S. Food and Drug Administration',1,'The FDA-approved drug labels for aripiprazole lauroxil (ARISTADA and ARISTADA INITIO) provide dosing guidance for CYP2D6 poor metabolizers (PMs). CYP2D6 PMs taking ARISTADA who are taking a concomitant medicine that is a strong CYP3A4 inhibitor should have their dose reduced to 441 mg. ARISTADA INITIO should be avoided in CYP2D6 poor metabolizers.'),
('PA166161536','Pharmaceuticals and Medical Devices Agency, Japan',0,'The PMDA package insert for atazanavir (Reyataz) contains pharmacogenetic information related to co-treatment with voriconazole and ritonavir: atazanavir exposure is expected to be decreased and voriconazole exposure is expected to be increased in patients who are CYP2C19 poor metabolizers.'),
('PA166163412','U.S. Food and Drug Administration',0,'Technivie (ombitasvir, paritaprevir and ritonavir) is indicated in combination with ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis. Within the clinical studies section, the label mentions frequency of the rs12979860 non-CC genotype.'),
('PA166163414','U.S. Food and Drug Administration',0,'The FDA-approved drug label for ustekinumab (STELARA) states that serious infections from mycobacteria, salmonella and BCG vaccinations have been reported in patients who are genetically deficient in IL-12/IL-23, and that diagnostic tests for these infections should be considered as dictated by clinical circumstances.'),
('PA166163417','U.S. Food and Drug Administration',0,'EPCLUSA (sofosbuvir and velpatasvir) is indicated for the treatment of adult patients with chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis, or with decompensated cirrhosis for use in combination with ribavirin. Within the clinical studies section, the label mentions frequency of the rs12979860 non-CC genotype.'),
('PA166163419','U.S. Food and Drug Administration',0,'Rucaparib (RUBRACA) is indicated for the treatment of patients with deleterious BRCA mutation-associated epithelial ovarian, fallopian tube or primary peritoneal cancer. Patients should be selected for therapy based on an FDA-approved companion diagnostic for RUBRACA.'),
('PA166163420','U.S. Food and Drug Administration',0,'Venetoclax (VENCLEXTA) is a BCL-2 inhibitor indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without the 17p deletion, as detected by an FDA-approved test, who have received at least one prior therapy. The label also notes whether mutation analyses detected mutations in the TP53, IDH1, IDH2, FLT3 and NPM1 genes. The label states that the 11q deletion was detected in 32% of patients in the MURANO study.'),
('PA166163421','U.S. Food and Drug Administration',0,'Daclatasvir (DAKLINZA) is indicated for use with sofosbuvir, with or without ribavirin, for the treatment of chronic HCV genotype 1 or 3 infection. Within the clinical studies section, the label mentions frequency of the rs12979860 non-CC genotype.'),
('PA166163422','U.S. Food and Drug Administration',0,'The FDA-approved drug label for dronabinol (SYNDROS) notes that patients who carry genetic variants that result in diminished CYP2C9 function may have a 2- to 3-fold higher dronabinol exposure.'),
('PA166163428','U.S. Food and Drug Administration',0,'HARVONI (ledipasvir and sofosbuvir) is indicated with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotype 1, 4, 5 or 6 infection. Within the clinical studies section, the label mentions frequency of the rs12979860 non-CC genotype.'),
('PA166163429','U.S. Food and Drug Administration',0,'The FDA-approved drug label for atezolizumab (TECENTRIQ) states that it is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma or metastatic non-small cell lung cancer. PD-L1 is encoded by the CD274 gene. The FDA-approved drug label for atezolizumab (TECENTRIQ) also states that it is approved for use in patients with EGFR or ALK genomic tumor aberrations and disease progression on other FDA-approved therapy.'),
('PA166163430','U.S. Food and Drug Administration',0,'Isosorbide dinitrate (dilatrate-SR) is indicated for the prevention of angina pectoris due to coronary artery disease. The FDA-approved drug label provides information about patients with cytochrome b5 reductase activity and risk for methemoglobinemia.'),
('PA166163431','U.S. Food and Drug Administration',0,'Isosorbide mononitrate (monoket) is indicated for the prevention and treatment of angina pectoris due to coronary artery disease. The FDA-approved drug label provides information about patients with cytochrome b5 reductase activity and risk for methemoglobinemia.'),
('PA166163433','U.S. Food and Drug Administration',0,'The FDA-approved drug label for eteplirsen (EXONDYS 51) states that it is an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping.'),
('PA166163435','U.S. Food and Drug Administration',0,'Olaratumab (LARTRUVO) is a platelet-derived growth factor receptor alpha (PDGFR-&alpha;) blocking antibody indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.'),
('PA166163439','U.S. Food and Drug Administration',0,'Elbasvir and grazoprevir (ZEPATIER) is indicated for the treatment of chronic hepatitis C virus (HCV) genotype 1 or 4 infection in adults. It is indicated for use with ribavirin in certain patient populations. Within the clinical studies section, the label mentions frequency of the rs12979860 non-CC genotype.'),
('PA166169877','U.S. Food and Drug Administration',0,'The FDA-approved drug label for avelumab (BAVENCIO) states that it is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of metastatic Merkel cell carcinoma and locally advanced or metastatic urothelial carcinoma. PD-L1 is encoded by the CD274 gene.'),
('PA166169878','U.S. Food and Drug Administration',0,'Brigatinib (ALUNBRIG) is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.'),
('PA166169880','U.S. Food and Drug Administration',0,'Cerliponase alfa (BRINEURA) is indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.'),
('PA166169882','U.S. Food and Drug Administration',1,'Deutetrabenazine (AUSTEDO) is indicated for treatment of chorea associated with Huntington''s disease. The maximum recommended dosage in poor CYP2D6 metabolizers is 36 mg per day (i.e. 18 mg twice daily).'),
('PA166169884','U.S. Food and Drug Administration',0,'The FDA-approved drug label for durvalumab (IMFINZI) states that it is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma or Stage III non-small cell lung cancer, both with certain qualifications. PD-L1 is encoded by the CD274 gene.'),
('PA166169912','U.S. Food and Drug Administration',0,'Enflurane (ETHRANE) is an inhalational anesthetic. The FDA-approved label warns that individuals with known or suspected genetic predisposition to malignant hyperthermia, or patients with Duchenne Muscular Dystrophy, are at greater risk of developing malignant hyperthermia, or hyperkaelemia, respectively.'),
('PA166169918','U.S. Food and Drug Administration',0,'The FDA-approved label for midostaurin (RYDAPT) states that it is indicated for the treatment of adult patients with acute myeloid leukemia that is FLT3 mutation-positive as detected by an FDA-approved test.'),
('PA166169920','U.S. Food and Drug Administration',0,'The FDA-approved label for niraparib (ZEJULA) states that clinical studies showed a significant improvement in progression-free survival for patients taking niraparib as compared with placebo in both patients with germline BRCA mutations and those without germline BRCA mutations.'),
('PA166170048','U.S. Food and Drug Administration',0,'Ribociclib (KISQALI) is indicated in combination with an aromatase inhibitor for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.'),
('PA166170052','U.S. Food and Drug Administration',0,'The FDA-approved drug label for valbenazine (INGREZZA) says to consider reducing the dose based on tolerability for known CYP2D6 poor metabolizers.'),
('PA166170929','U.S. Food and Drug Administration',0,'The FDA-approved drug label for gefinitib (IRESSA) states that it is indicated for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. The label also notes the potential clinical importance of considering CYP2D6 phenotype, though CYP2D6 testing is not mentioned.'),
('PA166170930','U.S. Food and Drug Administration',0,'The drug label for dabrafenib (TAFINLAR) states that it is indicated, as a single agent or in combination with trametinib, for patients with certain types of cancer. The label also notes that the drug may promote growth and development of malignancies with activation of RAS.'),
('PA166170931','U.S. Food and Drug Administration',0,'The FDA-approved label for midostaurin (RYDAPT) states that it is indicated for the treatment of adult patients with acute myeloid leukemia that is FLT3 mutation-positive as detected by an FDA-approved test. The label also notes the percentage of patients with an NPM1 mutation or KIT D816V mutation in clinical studies.'),
('PA166170932','U.S. Food and Drug Administration',0,'The FDA-approved drug label for pembrolizumab (KEYTRUDA) states that it is indicated for the treatment of patients with metastatic non-small cell lung cancer whose tumors express PD-L1 (CD274) as detected by an FDA-approved test. The label also mentions BRAF V600 mutations.'),
('PA166170933','U.S. Food and Drug Administration',0,'Pertuzumab (PERJETA) is a targeted antibody drug designed to bind to ERBB2 (HER2). The drug label notes that the pathological complete response rate was lower in patients with hormone receptor-positive tumors compared with hormone receptor-negative tumors.'),
('PA166170934','U.S. Food and Drug Administration',0,'The FDA-approved drug label for primaquine states that G6PD testing has to be performed before using the drug, and that it should not be prescribed for patients with severe G6PD deficiency. The label also notes that individuals with a family or personal history of nicotinamide adenine dinucleotide (NADH) methemoglobin reductase (CYB5R1-4) deficiency should be observed closely.'),
('PA166170935','U.S. Food and Drug Administration',0,'Rucaparib (RUBRACA) is indicated for the treatment of patients with deleterious BRCA mutation-associated epithelial ovarian, fallopian tube or primary peritoneal cancer. The label notes that rucaparib concentrations did not differ significantly based on CYP2D6 or CYP1A2 genotypes.'),
('PA166170936','U.S. Food and Drug Administration',0,'Tamoxifen (SOLTAMOX) is indicated for the treatment of breast cancer. A clinical trial showed no benefit of screening for Factor V Leiden (F5) or Prothrombin (F2) mutations when treating with tamoxifen.'),
('PA166170937','U.S. Food and Drug Administration',0,'Trametinib (MEKINIST) is indicated for use in patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, or metastatic non-small cell lung cancer with BRAF V600E mutation, as detected by an FDA-approved test. The label also notes that patients with a known history of G6PD deficiency were excluded from some clinical trials.'),
('PA166170938','U.S. Food and Drug Administration',0,'Trametinib (MEKINIST) is indicated for use in patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, or metastatic non-small cell lung cancer with BRAF V600E mutation, as detected by an FDA-approved test. The label also notes that dabrafenib may promote growth and development of malignancies with activitation of RAS (HRAS, KRAS, NRAS).'),
('PA166170939','U.S. Food and Drug Administration',0,'Trastuzumab (Herceptin) is used for the treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. The label also notes overall survival hazard ratios based on whether patients had hormone receptor-positive disease or hormone receptor-negative disease.'),
('PA166170957','U.S. Food and Drug Administration',0,'Vemurafenib (ZELBORAF) is a kinase inhibitor used to treat patients with unresectable or metastatic melanoma in cases where the BRAF V600E mutation is found by an FDA-approved test. The label notes that the drug may promote malignancies associated with activation of RAS (HRAS, KRAS, NRAS).'),
('PA166170958','U.S. Food and Drug Administration',0,'The FDA-approved drug label for valproic acid (Depakene) states that it is contraindicated in individuals with known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG), and suspected POLG-related disorders in children under 2 years old.'),
('PA166177475','U.S. Food and Drug Administration',0,'Abemaciclib (VERZENIO) is indicated in combination with other medications or as a monotherapy for the treatment of women with hormone receptor-positive, HER2-negative breast cancer.'),
('PA166177479','U.S. Food and Drug Administration',0,'Cariprazine (VRAYLAR) is an atypical antipsychotic used for the treatment of schizophrenia and bipolar disorder. The label notes that CYP2D6 poor metabolizer status does not have a clinically relevant effect on cariprazine pharmacokinetics.'),
('PA166177483','U.S. Food and Drug Administration',0,'Desvenlafaxine (PRISTIQ) is indicated for the treatment of adults with major depressive disorder. The label notes that the pharmacokinetics of the drug are similar in CYP2D6 poor metabolizers and CYP2D6 extensive metabolizers.'),
('PA166177486','U.S. Food and Drug Administration',0,'Enasidenib (IDHIFA) is an isocitrate dehydrogenase-2 (IDH2) inhibitor, indicated for the treatment of adult patients with acute myeloid leukemia with an IDH2 mutation.'),
('PA166177509','U.S. Food and Drug Administration',0,'Formoterol (PERFOROMIST) is indicated in patients with chronic obstructive pulmonary disease (COPD). The label notes that the effect of patients with CYP2D6 or CYP2C19 deficiency on formoterol exposure has not been adequately explored.'),
('PA166177512','U.S. Food and Drug Administration',0,'Inotuzumab ozogamicin (BESPONSA) is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The label notes that clinical studies included patients with Philadelphia chromosome-negative or -positive ALL.'),
('PA166177514','U.S. Food and Drug Administration',0,'Mirabegron (MYRBETRIQ) is indicated for the treatment of overactive bladder. The label notes that CYP2D6 poor metabolizers had increased concentrations of the drug as compared to CYP2D6 extensive metabolizers.'),
('PA166177516','U.S. Food and Drug Administration',0,'Neratinib (NERLYNX) is indicated for the treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.'),
('PA166177518','U.S. Food and Drug Administration',0,'VOSEVI (sofosbuvir, velpatasvir and voxilaprevir) is indicated for treatment of adult patients with chronic hepatitis C virus (HCV) infection. Within the clinical studies section, the label mentions frequency of the rs12979860 non-CC genotype.'),
('PA166177521','U.S. Food and Drug Administration',0,'Umeclidinium (INCRUSE ELLIPTA) is indicated for the treatment of patients with chronic obstructive pulmonary disease (COPD). The label notes that there was no clinically meaningful difference in exposure to the drug between patients who were CYP2D6 poor metabolizers and those who were CYP2D6 intermediate, extensive and ultrarapid metabolizers.'),
('PA166178724','U.S. Food and Drug Administration',0,'Neratinib (NERLYNX) is indicated for the treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer. The label notes the percentages of patients in clinical studies who had hormone receptor positive disease.'),
('PA166178750','U.S. Food and Drug Administration',1,'Metoclopramide (REGLAN) is indicated as a short-term treatment for adults with gastroesophageal reflux who fail to respond to conventional therapy. The label for metoclopramide notes that elimination of the drug may be slowed in CYP2D6 poor metabolizers, potentially increasing the risk for adverse reactions, and that these patients should receive a reduced dose of the drug.'),
('PA166179847','U.S. Food and Drug Administration',0,'The FDA-approved drug label for ivacaftor and tezacaftor combination (SYMDEKO) states that it is indicated for treatment of cystic fibrosis in patients age 12 years and older who are homozygous for the CFTR F508del mutation (rs113993960) or have at least one mutation in the CFTR gene that is responsive to ivacaftor and tezacaftor according to in vitro and/or clinical data.'),
('PA166179848','U.S. Food and Drug Administration',0,'The FDA-approved drug label for lofexidine (LUCEMYRA) states that although the pharmacokinetics of the drug have not been systematically evaluated in patients who do not express CYP2D6, it is likely that exposure to the drug would be increased in these patients.'),
('PA166179855','U.S. Food and Drug Administration',0,'The FDA-approved drug label for avatrombopag (DOPTELET) states that the risk for thrombosis should be considered in patients with risk factors for thromboembolism, including genetic prothrombotic conditions such as Factor V Leiden (F5), Prothrombin 20210A (F2), Antithrombin deficiency (SERPINC1) or Protein C (PROC) or S (PROS1) deficiency.'),
('PA166179870','U.S. Food and Drug Administration',0,'The FDA-approved drug label for binimetinib (MEKTOVI) states that it is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.'),
('PA166179871','U.S. Food and Drug Administration',0,'Binimetinib (MEKTOVI) states is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. The FDA-approved drug label also states that UGT1A1 genotype does not have a clinically important effect on binimetinib exposure.'),
('PA166179878','U.S. Food and Drug Administration',0,'The FDA-approved drug label for encorafenib (BRAFTOVI) states that it is indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.'),
('PA166179887','U.S. Food and Drug Administration',0,'The FDA-approved drug label for raltegravir (ISENTRESS) states that there is no evidence that common UGT1A1 polymorphisms alter raltegravir pharmacokinetics to a clinically meaningful extent, despite UGT1A1 being the primary enzyme involved in raltegravir elimination. However, the label notes that UGT1A1 activity is negligible at birth and provides dosing information based on neonatal age that takes into account increasing UGT1A1 activity.'),
('PA166180000','U.S. Food and Drug Administration',0,'The FDA-approved drug label for meclizine (ANTIVERT) states that CYP2D6 is the dominant metabolizing enzyme and that genetic polymorphism of CYP2D6 could contribute to large variability in meclizine exposure'),
('PA166181925','U.S. Food and Drug Administration',0,'The FDA-approved drug label for tamoxifen (SOLTAMOX) states that the impact of CYP2D6 polymorphisms on the efficacy of tamoxifen is not well established, but that CYP2D6 poor metabolizers have lower endoxifen concentrations are compared to intermediate, normal or ultrarapid metabolizers.'),
('PA166182021','U.S. Food and Drug Administration',1,'The FDA-approved drug label for amifampridine phosphate (FIRDAPSE) states that NAT2 poor metabolizers have higher concentrations of the drug as compared to normal metabolizers, and that the drug should be initiated at the lowest recommended starting dosage in these patients.'),
('PA166182280','U.S. Food and Drug Administration',0,'The FDA-approved drug label for dacomitinib (VIZIMPRO) states that it is indicated for the treatment of patients with metastatic non-small cell lung cancer with EGFR exon 19 deletion or exon 21 L858R mutations as detected by an FDA-approved test.'),
('PA166182719','U.S. Food and Drug Administration',0,'Ipilimumab (Yervoy) is a human cytotoxic T-lymphocyte antigen 4-blocking antibody indicated for: 1) unresectable or metastatic melanoma, 2) adjuvant treatment of melanoma, 3) advanced renal cell carcinoma, and 4) microsatellte instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer.'),
('PA166182721','U.S. Food and Drug Administration',0,'The FDA-approved label for erdafitinib (BALVERSA) states that it is a kinase inhibitor indicated for the treatment of adult patients'),
('PA166182722','U.S. Food and Drug Administration',0,'The FDA-approved label for erdafitinib (BALVERSA) states that it is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations and progressed during or following at least one line of prior platinum-containing chemotherapy. The label further states that erdafitinib plasma concentrations were predicted to be higher in patients with the CYP2C9*3/*3 genotype and to monitor for increased adverse reactions in patients who are known or suspected to have CYP2C9*3/*3 genotype.'),
('PA166182724','U.S. Food and Drug Administration',0,'Ixabepilone (IXEMPRA) in combination with capecitabine is indicated for the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline and a taxane. IXEMPRA as monotherapy is indicated for the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline, a taxane, and capecitabine. The label notes the percentages of patients in clinical studies who are hormone receptor positive or negative.'),
('PA166182725','U.S. Food and Drug Administration',0,'The FDA-approved label for eribulin (HALAVEN) states that it is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease and unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.'),
('PA166182726','U.S. Food and Drug Administration',0,'Rivaroxaban (XARELTO) is an anticoagulant with several indications, including for the reduction of risk of recurrence of deep vein thrombosis (DVT) or pulmonary embolism (PE). In a study of the efficacy of rivaroxaban in reducing the risk of recurrence of DVT or PE, mutations in F5 are mentioned as a risk factor for recurrence of DVT or PE.'),
('PA166182727','U.S. Food and Drug Administration',0,'The FDA-approved drug label for ivosidenib (TIBSOVO) states that it is indicated for the treatment of acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.'),
('PA166182728','U.S. Food and Drug Administration',0,'The FDA-approved drug label for ropivacaine (NAROPIN) states that patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and congenital methemoglobinemia (associated with variants in CYB5R3) are more susceptible to developing methemoglobinemia in association with use of local anesthetics.'),
('PA166182729','U.S. Food and Drug Administration',0,'The FDA-approved drug label for amoxapine contains information regarding the metabolism of tricyclic antidepressants by CYP2D6: CYP2D6 poor metabolizers may have higher plasma concentrations of tricyclic antidepressants, and the label suggests monitoring of plasma levels if this drug is co-administrered with a CYP2D6 inhibitor.'),
('PA166182730','U.S. Food and Drug Administration',0,'The FDA-approved drug label for amphetamine (ADZENYS ER) contains information about CYP2D6 and metabolism.'),
('PA166182734','U.S. Food and Drug Administration',0,'The FDA-approved drug label for larotrectinib (VITRAKVI) states that it is indicated for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.'),
('PA166182737','U.S. Food and Drug Administration',0,'The FDA-approved drug label for lidocaine and tetracaine (SYNERA) states that caution should be used in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency due to the risk for methemoglobinemia. Close monitoring for symptoms and signs of methemoglobinemia is recommended in this subset of patients.'),
('PA166182738','U.S. Food and Drug Administration',1,'The FDA-approved drug label for siponimod (MAYZENT) states that it is indicated for treatment of relapsing forms of multiple sclerosis (MS). Siponimod is contraindicated in patients with the CYP2C9*3/*3 genotype. Patients with the CYP2C9*1/*1, *1/*2 or *2/*2 genotypes should be given a daily maintenance dose of 2mg starting on Day 6 of treatment, while patients with the *1/*3 or *2/*3 genotypes should be given a daily maintenance dose of 1mg starting on Day 5 of treatment.'),
('PA166182739','U.S. Food and Drug Administration',0,'The FDA-approved drug label for tafenoquine states that G6PD testing must be performed before prescribing the drug, and that tafenoquine is contraindicated in patients with G6PD deficiency or of unknown G6PD status.'),
('PA166182741','U.S. Food and Drug Administration',0,'The FDA-approved drug label for articaine and epinephrine (ORABLOC) states that individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency or congenital methemoglobinemia may be at increased risk for treatment-induced methemoglobinemia.'),
('PA166182742','U.S. Food and Drug Administration',0,'The FDA-approved label for talazoparib (TALZENNA) states that it is indicated for use in patients with deleterious or suspected deleterious germline BRCA mutations and HER2-negative locally advanced or metastatic breast cancer.'),
('PA166182744','U.S. Food and Drug Administration',0,'The FDA-approved drug label for lorlatinib (LORBRENA) states that it is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on: crizotinib and at least one other ALK inhibitor for metastatic disease; or alectinib as the first ALK inhibitor therapy for metastatic disease; or ceritinib as the first ALK inhibitor therapy for metastatic disease.'),
('PA166182746','U.S. Food and Drug Administration',0,'The FDA-approved drug label for ceftriaxone (ROCEPHIN) states that individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency or congenital methemoglobinemia may be at increased risk for treatment-induced methemoglobinemia.'),
('PA166182747','U.S. Food and Drug Administration',0,'The FDA-approved drug label for lorlatinib (LORBRENA) states that it is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). Loratinib has in vitro activity against ALK and ROS1 and adverse reactions observed in clinical trials consist of patients with ALK-positive or ROS1-positive metastatic NSCLC who received LORBRENA.'),
('PA166182749','U.S. Food and Drug Administration',0,'The FDA-approved drug label for lusutrombopag (MULPLETA) states that the potential increased risk for thrombosis should be considered in patients with risk factors for thromboembolism, including genetic prothrombotic conditions such as Factor V Leiden (F5), Prothrombin 20210A (F2), Antithrombin deficiency (SERPINC1) or Protein C (PROC) or S (PROS1) deficiency.'),
('PA166182750','U.S. Food and Drug Administration',0,'The FDA-approved drug label for toremifene (FARESTON) states that it is indicated for the treatment of estrogen-receptor positive or unknown metastatic breast cancer.'),
('PA166182751','U.S. Food and Drug Administration',0,'The FDA-approved drug label for mepivacaine states that patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency and congenital methemoglobinemia may be more susceptible to developing clinical manifestations of methemoglobinemia. Close monitoring for symptoms and signs of methemoglobinemia is recommended in this subset of patients.'),
('PA166182752','U.S. Food and Drug Administration',0,'The FDA-approved label for talazoparib (TALZENNA) states that it is indicated for use in patients with deleterious or suspected deleterious germline BRCA mutations and HER2-negative locally advanced or metastatic breast cancer.'),
('PA166182753','U.S. Food and Drug Administration',0,'The FDA-approved drug label for meloxicam (QMIIZ ODT) states that in adult patients known or suspected to be poor CYP2C9 metabolizers, consider dose reduction, and monitor these patients for adverse effects.'),
('PA166182755','U.S. Food and Drug Administration',0,'The FDA-approved drug label for vincristine (MARQIBO) states that it is indicated for the treatment of Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.'),
('PA166182757','U.S. Food and Drug Administration',0,'The FDA-approved drug label for inotersen (TEGSEDI) states that TEGSEDI is a transthyretin-directed antisense oligonucleotide indicated for treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.'),
('PA166182758','U.S. Food and Drug Administration',0,'The FDA-approved label for goserelin (ZOLADEX) states that it is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for 1) combination use with flutamide for the management of locally confined carcinoma of the prostate, 2) palliative treatment of advanced carcinoma of the prostate or advanced breast cancer in pre- and perimenopausal women, 3) management of endometriosis, 4) use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding.'),
('PA166182759','U.S. Food and Drug Administration',0,'The FDA-approved drug label for chloroprocaine (Nesacaine) states that individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency or congenital methemoglobinemia may be at increased risk for treatment-induced methemoglobinemia.'),
('PA166182760','U.S. Food and Drug Administration',0,'The FDA-approved drug label for docetaxel mentions subset analysis for Breast Cancer patients defined by positive estrogen and/or progesterone receptor status.'),
('PA166182762','U.S. Food and Drug Administration',0,'The FDA-approved drug label for elagolix (ORILISSA) states that higher plasma concentrations of the drug have been seen in small groups of patients homozygous for the SLCO1B1 rs4149056 CC variant.'),
('PA166182764','U.S. Food and Drug Administration',0,'Emapalumab (GAMIFANT) is indicated for hemophagocytic lymphohistiocytosis (HLH): the FDA label lists some of the genes associated with HLH in patients in the NI-0501-04 clinical study.'),
('PA166182765','U.S. Food and Drug Administration',0,'The FDA-approved drug label for flutamine (EULEXIN) states that in patients susceptible to aniline toxicity (eg, persons with glucose-6-phosphate dehydrogenase deficiency, hemoglobin M disease, and smokers), monitoring of methemoglobin levels should be considered.'),
('PA166182766','U.S. Food and Drug Administration',0,'The FDA-approved drug label for fosphenytoin (CEREBYX) states that limited evidence suggests that HLA-B*15:02 may be a risk factor for the development of Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) in patients of Asian ancestry taking other antiepileptic drugs associated with SJS/TEN, including phenytoin. Consideration should be given to avoiding CEREBYX as an alternative for carbamazepine patients'),
('PA166182768','U.S. Food and Drug Administration',0,'The FDA-approved label for gilteritinib (XOSPATA) states that it is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.'),
('PA166182769','U.S. Food and Drug Administration',0,'The FDA-approved drug label for hydroxychloroquine (PLAQUENIL) states that it should be administered with caution in patients having glucose-6-phosphate dehydrogenase (G6PD) deficiency and that hemolysis was reported in individuals with'),
('PA166182786','U.S. Food and Drug Administration',0,'The FDA-approved drug label for tolazamide states that, due to the risk of hemolytic anemia, caution should be used when administering tolazamide to patients with G6PD deficiency.'),
('PA166182787','U.S. Food and Drug Administration',0,'The FDA-approved drug label for tolbutamide states that, due to the risk of hemolytic anemia, caution should be used when administering tolbutamide to patients with G6PD deficiency.'),
('PA166182788','Health Canada Santé Canada',0,'The HCSC-approved product monograph for tolbutamide (APO-TOLBUTAMIDE) states that, due to the risk of hemolytic anemia, caution should be used when administering tolbutamide to patients with G6PD deficiency.'),
('PA166182789','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) states that toremifene (FARESTON) is not recommended for patients with metastatic breast cancer who have estrogen receptor negative tumors.'),
('PA166182886','U.S. Food and Drug Administration',0,'The FDA-approved drug label for migalastat states that it is for the treatment of adults with Fabry disease and an &quot;amenable&quot; GLA variant.'),
('PA166182890','U.S. Food and Drug Administration',0,'The FDA-approved drug label for olaparib (Lynparza) states that it is indicated for treatment of adult patients ovarian or breast cancer. The label also notes that patients with hormone receptor positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy.'),
('PA166182923','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for abemaciclib (Verzenios) states that it is indicated for the treatment of women with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.'),
('PA166182924','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for alectinib (Alecensa) states that it is indicated for the first-line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC), or ALK-positive advanced NSCLC previously treated with crizotinib.'),
('PA166182925','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for amifampridine (FIRDAPSE) states that exposure to the drug is influenced by the acetylation activity of NAT enzymes and the NAT2 genotype, and that slow acetylators experienced more adverse reactions as compared to fast acetylators.'),
('PA166182926','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for atezolizumab (Tecentriq) states that it is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) after prior platinum-containing chemotherapy or who are considered cisplatin ineligible, and whose tumors have a PD-L1 expression &gt;= 5%, among other indications.'),
('PA166182928','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for binimetinib (Mektovi) states that it is indicated in combination with encorafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.'),
('PA166182929','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for binimetinib (Mektovi) states that it is indicated in combination with encorafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. The EPAR also states that there is no apparent relationship observed between binimetinib exposure and UGT1A1 mutation status.'),
('PA166182930','European Medicines Agency',1,'The EMA European Public Assessment Report (EPAR) for brexpiprazole (RXULTI) states that known CYP2D6 poor metabolizers should receive half the recommended dose, and known CYP2D6 poor metabolizers taking strong or moderate CYP3A4 inhibitors should receive a quarter of the recommended dose.'),
('PA166182931','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for brigatinib (Alunbrig) states that it is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer previously treated with crizotinib.'),
('PA166182932','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for brivaracetam (Briviact) states that individuals with ineffective mutations of CYP2C19 had decreased production of the hydroxy metabolite and increased concentrations of brivaracetam.'),
('PA166182934','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for cerliponase alfa (Brineura) states that it is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.'),
('PA166182940','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for cholic acid (Orphacol) states that it is indicated for the treatment of inborn errors in primary bile acid synthesis due to deficiencies in the proteins encoded by the HSD3B7 and AKR1D1 genes. The EPAR for cholic acid (Kolbam) is indicated for deficiencies in the proteins encoded by the CYP27A1, AMACR and CYP7A1 genes.'),
('PA166182941','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for cobimetinib (Cotellic) states that it is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutations.'),
('PA166182942','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for dacomitinib (Vizimpro) states that it is indicated for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR-activating mutations,'),
('PA166182943','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for dolutegravir (Tivicay) states that subjects with UGT1A1 genotypes that confer poor dolutegravir metabolism had a 32% lower clearance and 46% higher AUC as compared to subjects with UGT1A1 genotypes that confer normal dolutegravir metabolism.'),
('PA166182944','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for duloxetine (Cymbalta) states that the pharmacokinetics of the drug have large intersubject variability partly due to gender, age, smoking status and CYP2D6 metabolizer status. Limited data suggests that concentrations of duloxetine are higher in CYP2D6 poor metabolizers.'),
('PA166182945','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for efavirenz (Sustiva) states that patients with the CYP2B6*6/*6 genotype had higher Cmax as compared to patients with the CYP2B6*1/*1 genotype, and the mean QTc prolongation was 8.7 ms. The label also notes that plasma exposure may be increased in patients with the rs3745274 TT genotype (G516T).'),
('PA166182947','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for elosulfase alfa (Vimizim) states that it is indicated for patients with mucopolysaccharidosis type IVA, also known as Morquio A syndrome. This disease results from deficiency or marked reduction of the galactosamine (N-acetyl)-6-sulfatase (GALNS) enzyme.'),
('PA166182948','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for encorafenib (Braftovi) states that it is indicated in combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.'),
('PA166182949','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for erlotinib (Tarceva) states that patients with low expression levels of UGT1A1 or genetic glucuronidation disorders such as Gilbert''s disease may have increased concentrations of bilirubin and should be treated with caution.'),
('PA166182950','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for gefitinib (IRESSA) states that no specific dose adjustment is recommended in patients with known CYP2D6 poor metabolizer genotype, but these patients should be closely monitored for adverse events. The EPAR also states that mean exposure to gefitinib was 2-fold higher in poor metabolizers as compared to extensive metabolizers, and that these higher exposures may be clinically relevant.'),
('PA166182951','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for glibenclamide (AMGLIDIA) states that it should not be prescribed in patients with G6PD deficiency, and that use of an alternative treatment is strongly recommended.'),
('PA166182952','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for irinotecan (ONIVYDE) states that a reduced starting dose of 50 mg/m2 should be considered for patients with the UGT1A1*28/*28 genotype, with a dose increase to 70 mg/m2 if tolerated in subsequent cycles. Individuals with the UGT1A1*28/*28 genotype are at increased risk for neutropenia.'),
('PA166182953','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for ivacaftor and lumacaftor (Orkambi) states that it is indicated for the treatment of cystic fibrosis in patients aged 6 years and older who are homozygous for the F508del mutation in the CFTR gene.'),
('PA166182954','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for ivacaftor and tezacaftor (Symkevi) states that it is indicated for the treatment of patients with cystic fibrosis aged 12 years and older who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A-&gt;G, S945L, S977F, R1070W, D1152H, 2789+5G-&gt;A, 3272-26A-&gt;G, 3849+10kbC-&gt;T.'),
('PA166182961','U.S. Food and Drug Administration',0,'Duvelisib (COPIKTRA) is indicated for various leukemia types and the FDA label mentions that some patients had the 17p chromosomal deletion.'),
('PA166183171','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for lacosamide (Vimpat) states that no clinically relevant difference in lacosamide exposure was seen when comparing CYP2C19 extensive metabolizers and CYP2C19 poor metabolizers.'),
('PA166183172','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for lapatinib (Tyverb) states that patients with the HLA-DQA1*02:01 and HLA-DRB1*07:01 alleles have an increased risk of hepatotoxicity.'),
('PA166183181','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for lesinurad (Zurampic) states that patients who are known CYP2C9 poor metabolizers should be treated with caution due to an increased risk for renal-related adverse effects.'),
('PA166183183','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for lidocaine and prilocaine (Fortacin) states that patients or their partner with G6PD deficiency are more susceptible to methemoglobinemia.'),
('PA166183184','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for lorlatinib (Lorviqua) states that it is indicated for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after various previous treatments.'),
('PA166183200','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for midostaurin (Rydapt) states that it is indicated for treatment of adults with acute myeloid leukemia who are FLT3 mutation-positive.'),
('PA166183209','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for migalastat (Galafold) states that it is for the treatment of adults and adolescents age 16 years and older with Fabry disease and an &quot;amenable&quot; GLA variant.'),
('PA166183219','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for mirabegron (Betmiga) states that CYP2D6 genetic polymporphisms have a minimal impact on exposure to mirabegron and no dose adjustment is needed when administered to patients who are CYP2D6 poor metabolizers.'),
('PA166183220','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for neratinib (Nerlynx) states that it is indicated for the treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.'),
('PA166183243','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for olaparib (Lynparza) in 50 mg hard capsules states that it is indicated for treatment of BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. Olaparib (Lynparza) in 100 or 150 mg film-coated tablets is indicated for patients with germline BRCA1/2-mutations with HER2 negative breast cancer, among other indications.'),
('PA166183246','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for osimertinib (TAGRISSO) states that it is indicated for the treatment of adult patients with non-small cell lung cancer (NSCLC) with activating EGFR mutations or EGFR T790M mutation.'),
('PA166183247','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for palbociclib (IBRANCE) states that it is indicated for the treatment of hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer.'),
('PA166183248','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for palonosetron (Aloxi) states that pharmacokinetic parameters are not significantly different between CYP2D6 poor and extensive metabolizers.'),
('PA166183249','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for pembrolizumab (KEYTRUDA) states that it is indicated for the treatment of certain cancers whose tumors express PD-L1 (CD274), among other indications.'),
('PA166183251','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for raltegravir (ISENTRESS) states that the geometric mean ratio of AUC was 1.41 in patients with the UGT1A1*28/*28 genotype and 1.91 in patients with the UGT1A1 wild-type genotype, and that dose adjustment is not necessary based on UGT1A1 genotype.'),
('PA166183421','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for ribociclib (Kisqali) states that it is indicated for the treatment of women with hormone receptor positive, HER2-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.'),
('PA166183423','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for rucaparib (Rubraca) states that one of the indications is as a monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA-mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy.'),
('PA166183424','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for rucaparib (Rubraca) states that no clinically relevant pharmacokinetic differences were observed among patients with different CYP2D6 or CYP1A2 phenotypes.'),
('PA166183425','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for talazoparib (Talzenna) states that it is indicated as a monotherapy for the treatment of adult patients with germline BRCA1 or BRCA2 mutations, who have HER2-negative locally advanced or metastatic breast cancer.'),
('PA166183441','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for umeclidinium (Incruse Ellipta) states that there is no evidence of any clinically significant effect of CYP2D6 genetic polymorphism on systemic exposure to umeclidinium.'),
('PA166183442','European Medicines Agency',0,'The EMA European Public Assessment Report (EPAR) for vandetanib (Caprelsa) states that RET mutation testing is recommended, since patients without RET mutation may have a decreased benefit from vandetanib treatment.'),
('PA166183563','Swissmedic',0,'The Swiss drug label for abacavir (Ziagen) states that patients should be screened for the presence of HLA-B*57:01 prior to starting treatment with abacavir. Ziagen is contraindicated in carriers of the HLA-B*57:01 allele.'),
('PA166183590','Swissmedic',0,'The Swiss drug label for maraviroc (Celsentri) states that CYP3A5 genotypes may affect the exposure to maraviroc.'),
('PA166183593','Swissmedic',0,'The Swiss drug label for acenocoumarol (Sintrom) states that patients with the CYP2C9*2 or *3 variants have reduced clearance of acenocoumarol.'),
('PA166183621','Swissmedic',0,'The Swiss drug label for mefloquine (Mephaquin Lactab) states that there''s no in vitro or in vivo evidence to suggest hemolysis to be associated with glucose-6-phosphate dehydrogenase deficiency in patients treated with mefloquine.'),
('PA166183782','Swissmedic',0,'The Swiss drug label for aspirin (Aspirin Cardio 100/300, Aspirin, Aspirin-C) states that acetylsalicylic acid could induce hemolysis or hemolytic anemia in patients with G6PD deficiency.'),
('PA166183783','Swissmedic',0,'The Swiss drug label for allopurinol (Zyloric) states that in patients with the HLA-B*58:01 allele, use of allopurinol may be considered if the benefits are considered greater than the risks. However, increased attention to signs of hypersensitivity reaction or SJS/TEN is required.'),
('PA166183784','Swissmedic',0,'The Swiss drug label for amifampridine (Firdapse) states that patients who are NAT2 slow acetylators may have higher exposure to the drug and more adverse effects as compared to fast acetylators'),
('PA166183786','Swissmedic',0,'The Swiss drug label for amlodipine, atorvastatin and perindopril arginine (Triveram) states that patients with G6PD deficiency may experience hemolytic anemia. Additionally, patients with the SLCO1B1 rs4149056 CC genotype may have higher atorvastatin exposure which may increase the risk of rhabdomyolysis.'),
('PA166183789','Swissmedic',0,'The Swiss drug label for metabutethamin (Alcacyl® 500 Instant-Pulver) states that patients with G6PD deficiency may have increased risk of adverse events to metabutethamin and caution is advised.'),
('PA166183790','Swissmedic',0,'The Swiss drug label for metoprolol (Beloc ZOK, Logimax) states that CYP2D6 genotypes may affect the plasma concentration of metoprolol.'),
('PA166183810','Swissmedic',0,'The Swiss drug label for mirabegron (Betmiga) states that CYP2D6 genetic polymorphism has minimal effect on mean plasma exposure to mirabegron.'),
('PA166183881','Swissmedic',0,'The Swiss drug label for mivacurium chlorid (Mivacron) states that BCHE genotypes may affect the response to mivacurium chlorid.'),
('PA166183900','Swissmedic',0,'The Swiss drug label for moclobemid (Aurorix) states that the metabolism of moclobemide may be affected in genetically induced or drug-induced slow metabolisers. Caution is recommended when using moclobemide with drugs that are metabolized by CYP2C19 as moclobemide inhibits this enzyme.'),
('PA166183901','Swissmedic',0,'The Swiss drug label for moxifloxacin (Avalox) states that moxifloxacin should be used with caution in patients with G6PD deficiency.'),
('PA166183910','Swissmedic',0,'The Swiss drug label for nebivolol (Nebilet) states that nebivolol is metabolized by CYP2D6. However, the active metabolites achieve a similar effect in the rapidly and slowly metabolizing patients.'),
('PA166184082','Swissmedic',0,'The Swiss drug label for nicorendil (Dancor 10/20) states that patients with glucose-6-phosphate dehydrogenase deficiency should use Dancor with caution.'),
('PA166184108','Swissmedic',0,'The Swiss drug labels for fluorouracil/salicylic acid (Actikerall and Verrumal) state that, where appropriate, DPYD activity levels should be determined prior to fluorouracil treatment.'),
('PA166184109','Swissmedic',0,'The Swiss drug label for aripiprazole (Abilify) states that CYP2D6 poor metabolizers who take aripiprazole with a concomitant strong CYP3A4 inhibitor may have increased plasma concentrations of aripiprazole compared to CYP2D6 normal metabolizers.'),
('PA166184110','Swissmedic',1,'The Swiss drug labels for vitamin C (Streuli, Callimon and Revitalose) state that high doses of vitamin C should be avoided in patients with G6PD deficiency.'),
('PA166184111','Swissmedic',0,'The Swiss drug label for atomoxetine (Srattera) states that caution should be exercised when CYP2D6 poor metabolizers take atomoxetine at the same time other cytochrome P450 inhibitors, as there is a risk of increasing the plasma concentrations of atomoxetine.'),
('PA166184112','Swissmedic',1,'The Swiss drug label for azathioprine (Imurek) states that a dose reduction is generally required for patients carrying NUDT15 variants and notes that patients with TPMT deficiency are sensitive to the myelosuppressive effect of azathioprine.'),
('PA166184113','Swissmedic',0,'The Swiss drug label for bisoprolol fumarate/perindopril arginine (Cosyrel) states that patients with G6PD deficiency may experience hemolytic anemia as a result of bisoprolol fumarate/perindopril arginine treatment.'),
('PA166184114','Swissmedic',1,'The Swiss drug label for capecitabine (Xeloda) states that capecitabine is contraindicated in patients with low or no DPYD activity. Patients with partial DPYD deficiency may be given capecitabine at a significantly reduced dose if the benefit of the drug is deemed to outweigh the risks.'),
('PA166184115','Swissmedic',0,'The Swiss drug label for carbamazepine (Tegretol) recommends that patients of certain ancestries be tested for the presence of the HLA-A*31:01 allele before beginning carbamazepine therapy. Carbamazepine should be avoided in patients carrying the HLA-A*31:01 allele unless the benefits clearly outweigh the risks.'),
('PA166184117','Swissmedic',0,'The Swiss drug label for carbasalate calcium (Alcacyl) states that carbasalate calcium shoudl be used with caution in patients with G6PD deficiency.'),
('PA166184118','Swissmedic',0,'The Swiss drug label for carvedilol (Dilatrend) states that CYP2D6 &quot;slow metabolizers&quot; have increased plasma concentrations of R- S-carvedilol. However, this is thought to be of limited clinical significance.'),
('PA166184119','Swissmedic',0,'The Swiss drug label for celecoxib (Celebrex) states that celecoxib should be used with caution in patients who are known or suspected to be CYP2C9 &quot;slow metabolizers&quot;.'),
('PA166184120','Swissmedic',0,'The Swiss drug label for quinine (Chininsulfat 250 Hänseler) states that quinine is contraindicated in patients with G6PD deficiency.'),
('PA166184121','Swissmedic',0,'The Swiss drug label for chloroquine (Nivaquine) states that chloroquine is contraindicated in patients with G6PD deficiency.'),
('PA166184122','Swissmedic',0,'The Swiss drug label for ciprofloxacin (Ciproxin) states that ciprofloxacin should be used with caution in patients with G6PD deficiency.'),
('PA166184123','Swissmedic',1,'The Swiss drug label for citalopram (Seropram) states that variants in both CYP2D6 and CYP2C19 can affect metabolism of citalopram. Patients who have reduced CYP2C19 metabolism should be given a reduced dose of citalopram.'),
('PA166184124','Swissmedic',0,'The Swiss drug label for clomipramine (Anafranil) states that patients with reduced CYP2D6 activity may have high plasma concentrations of desmethylclomipramine, a metabolite of clomipramine.'),
('PA166184125','Swissmedic',1,'The Swiss drug label for clopidogrel (Plavix) states that clopidogrel has a reduced efficacy in CYP2C19 &quot;slow metatoblizers&quot; and a dose increase should be considered for these patients.'),
('PA166184126','Swissmedic',0,'The Swiss drug label for codeine (Codein Knoll) states that codeine is contraindicated in patients with a CYP2D6 ultrarapid metabolizer phenotype.CYP2D6 &quot;slow metabolizers&quot; may experience reduced or no analgesia from codeine.'),
('PA166184127','Swissmedic',0,'The Swiss drug label for acetaminophen/codeine (Co-Dafalgan) states that CYP2D6 genotyping hsould be carried out in breastfeeding mothers prior to analgesic therapy as acetaminophen/codeine is contraindicated in patients with a CYP2D6 ultrarapid metabolizer phenotype. Patients with a CYP2D6 poor metabolizer phenotype do not experience an analgesic effect from codeine.'),
('PA166184128','Swissmedic',0,'The Swiss drug label for acetaminophen/codeine (Co-Dafalgan) states that acetaminophen (paracetamol) should be used with caution in patients with G6PD deficiency.'),
('PA166184129','Swissmedic',0,'The Swiss drug label for daclatasvir (Daklinza) states that response to daclatasvir is not dependent on IFNL3 (IL28B) genotype.'),
('PA166184130','Swissmedic',1,'The Swiss drug label for dapoxetine (Priligy) states that dapoxetine should be used with caution in CYP2D6 &quot;slow metabolizers&quot; and that the dose of dapoxetine should not be increased to 60mg in these patients.'),
('PA166184131','Swissmedic',0,'The Swiss drug label for darifenacin (Emselex) states that CYP2D6 poor metabolizers who are taking darifenacin with a concomitant strong CYP3A4 inhibitor may have significantly increased exposure to darifenacin.'),
('PA166184132','Swissmedic',0,'The Swiss drug label for dasabuvir (Exviera) states that patients with an IFNL3 (IL28B) CC genotype have an increased sustained viral response than patients with the CC genotype.'),
('PA166184133','Swissmedic',0,'The Swiss drug label for dexlansoprazole (Dexilant) states that CYP2C19 poor metabolizers have increased exposure to dexlansoprazole compared to normal metabolizers. CYP2C19 metabolizer phenotype can also affect the nature of some drug-drug interactions involving dexlansoprazole.'),
('PA166184134','Swissmedic',0,'The Swiss drug label for dextromethorphan (Bexin) states that metabolism and elimination of dextromethorphan are delayed in CYP2D6 &quot;slow metabolizers&quot;.'),
('PA166184155','Swissmedic',0,'The Swiss drug label for nitrofurantoin (Uvamin retard) states that breastfeeding of infants suspected or known to suffer from erythrocyte enzyme deficiency (including G6PD deficiency) should be avoided as traces of nitrofurantoin are found in breast milk.'),
('PA166184156','Swissmedic',0,'The Swiss drug label for norfloxacin (Norsol) states that patients with G6PD deficiency may experience hemolytic anemia.'),
('PA166184157','Swissmedic',0,'The Swiss drug label for ofloxacin (Tarivid) states that ofloxacin should be used with caution in patients with G6PD deficiency due to increased risk of hemolytic reactions.'),
('PA166184158','Swissmedic',0,'The Swiss drug label for Ombitasvir/Paritaprevir/Ritonavir (Viekirax) states that IFNL3/4 (previously known as IL28B) genotypes may affect the efficacy of Viekirax.'),
('PA166184159','Swissmedic',0,'The Swiss label for omeprazole (Antramups®, Tabletten) states that CYP2C19 is involved in the metabolism of the drug, and that slow metabolizers have a greater systemic exposure to omeprazole than that of fast metabolizers.'),
('PA166184160','Swissmedic',0,'The Swiss label for ondansetron (Zofran®/- Zydis®) states that CYP3A4, CYP2D6 and CYP1A2 are involved in ondansetron metabolism. However, the overall rate of ondansetron elimination will hardly be affected by the absence of one enzyme (e.g. genetic CYP2D6 deficiency).'),
('PA166184172','Swissmedic',0,'The Swiss label for opium derivatives und expectorants (Codicalm Sirup) states that codeine metabolism is mediated by CYP2D6 and CYP2D6 &quot;ultra-fast metabolizers&quot; may show symptoms of overdose, such as dizziness, deep sedation, shortness of breath, nausea and vomiting, to respiratory and cardiac arrest.'),
('PA166184173','Swissmedic',0,'The Swiss label for oxcarbazepine (Apydan® extent) states that patients who have an increased risk of SJS/TEN should be tested for the presence of the allele HLA-B*1502 before starting treatment with Apydan extent. &quot;In case of a positive result, Apydan extent should not be used unless the benefit is clearly greater than the risk. It should be considered that HLA-B*1502 is also a risk factor for other antiepileptic drugs&quot;.'),
('PA166184177','Swissmedic',0,'The Swiss label for oxycodone (Oxycontin or Targin) states that genetic polymorphisms of CYP2D6 can alter the efficacy of oxycodone or lead to undesired effects.'),
('PA166184220','Swissmedic',0,'The Swiss label for paliperidon (Trevicta) states that no discernible difference between extensive metabolisers and slow metabolisers of CYP2D6 substrates with respect to apparent clearance of paliperidone after application of oral paliperidone.'),
('PA166184221','Swissmedic',0,'The Swiss drug label for palonosetron (Aloxi) states that the CYP2D6 genetic polymorphism does not significantly influence the overall body clearance of palonosetron compared to healthy individuals and no dose adjustment is necessary.'),
('PA166184222','Swissmedic',0,'The Swiss label for pantoprazole (Pantozol 20/40/- i.v.) states that individuals with CYP2C19 enzyme deficiency (poor metabolizers) may have increased pantoprazole concentration as compared to individuals with intact CYP2C19 enzyme activity (extensive metabolizers).'),
('PA166184223','Swissmedic',0,'The Swiss drug label for Paracetamol (acetaminophen), combinations excl. Psycholeptics (Vicks MediNait® Sirup) states that patients with Glucose-6-phosphate dehydrogenase deficiency may have risk for hemolytic anemia and patients with CYP2D6 deficiency may have altered drug metabolism.'),
('PA166184224','Swissmedic',0,'The Swiss drug label for Paracetamol, Tramadol hydrochlorid (Tramadol plus Spirig HC) states that patients with Glucose-6-phosphate dehydrogenase deficiency may have risk for hemolytic anemia.'),
('PA166184231','Swissmedic',0,'The Swiss drug label for umeclidinium (Incruse Ellipta) states that umeclidinium exposure is not affected by CYP2D6 genotype.'),
('PA166184232','Swissmedic',0,'The Swiss drug label for venlafaxine (Efexor ER) states that CYP2D6 poor metabolizers experience a greater increase in the AUCs of venlafaxine and O-desmethylvenlafaxine when treated with concomitant ketoconazole compared to normal metabolizers.'),
('PA166184234','Swissmedic',0,'The Swiss drug label for vernakalant (Brinavess) outlines the differences in venlafaxine metabolism and clearance between CYP2D6 normal metabolizers and &quot;weak metabolizers&quot; but states that these differences do not require a dose adjustment to be made.'),
('PA166184236','Swissmedic',0,'The Swiss drug label for umeclidinium/vilanterol (Anoro® Ellipta®) states that umeclidinium exposure is not affected by CYP2D6 variants.'),
('PA166184237','Swissmedic',0,'The Swiss drug label for vitamin B complex with vitamin C (Begrocit) states that overdose of vitamin C can cause hemolysis in patients with G6PD deficiency.'),
('PA166184238','Swissmedic',0,'The Swiss drug label for voriconazole (Vfend) states that voriconazole levels are increased in patients who are CYP2C19 intermediate or poor metabolizers.'),
('PA166184239','Swissmedic',0,'The Swiss drug label for vortioxetine (Brintellix) states that plasma concentrations of vortioxetine are increased in CYP2D6 &quot;slow metabolizers&quot; compared to normal metabolizers.'),
('PA166184268','Swissmedic',0,'The Swiss drug label for pazopanib (Votrient) states that patients who carry the HLA-B*57:01 allele may have a higher risk of votrient-induced ALT elevation.'),
('PA166184286','Swissmedic',0,'The Swiss drug label for perindopril (COVERSUM N 5 mg/10 mg) states that patients with congenital G6PD deficiency may have risk for haemolytic anaemia.'),
('PA166184345','Swissmedic',1,'The Swiss drug label for phenytoin (Phenytoin-Gerot) states that HLA-B*1502 may be associated with an increased risk of Stevens-Johnson syndrome (SJS) in individuals of Thai or Han Chinese descent treated with phenytoin and the use of phenytoin should only be considered if the benefit is considered higher than the risks for these patients known to carry HLA-B*5102.'),
('PA166184373','Swissmedic',0,'The Swiss label for piroxicam (Felden) states that CYP2C9 variants may impact the systemic exposure and elimination half-life of piroxicam.'),
('PA166184374','Swissmedic',0,'The Swiss drug label for ibrutinib (IMBRUVICA) states that no precautions are required in patients with different CYP2D6 genotypes.'),
('PA166184377','Swissmedic',0,'The Swiss drug labels for indacaterol (Onbrez Breezhaler) and indacaterol and glycopyrronium bromide (Ultibro Breezhaler) states that the UGT1A1 (TA)7(TA)7 genotype is associated with marginally increased exposure to indacaterol.'),
('PA166184378','Swissmedic',1,'The Swiss drug label for irinotecan (Onivyde) gives dosing changes for patients homozygous for UGT1A1*28.'),
('PA166184380','Swissmedic',0,'The Swiss drug label for brivaracetam (Briviact) discusses metabolism of brivaracetam by CYP2C19 and CYP2C9 and changes in pharmacokinetics in CYP2C19 poor metabolizers.'),
('PA166184381','Swissmedic',0,'The Swiss drug label for prilocaine (Oraqix) cautions that patients with G6PD may be at increased risk for methemoglobinemia.'),
('PA166184382','Swissmedic',0,'The Swiss drug label for lansoprazole (Agopton) states that CYP2C19 poor metabolizers have increased exposure to lansoprazole compared to normal metabolizers.'),
('PA166184383','Swissmedic',0,'The Swiss drug label for lapatinib (Tyverb) cautions for increased risk of drug induced liver injury in carriers of the HLA alleles DQA1*02:01 and DRB1*07:01.'),
('PA166184385','Swissmedic',0,'The Swiss drug label for lesinurad (Zurampic) gives information about CYP2C9 slow metabolizers and pharmacokinetics.'),
('PA166184386','Swissmedic',0,'The Swiss drug label for letermovir (Prevymis) gives information about variants in UGT1A1 and SLCO1B1 that were tested for association with letermovir pharmacokinetics although no clinically relevant effects were observed.'),
('PA166184388','Swissmedic',0,'The Swiss drug label for losartan (Cosaar) gives information on CYP2C9 and CYP3A4 involvement in formation of active metabolites of losartan.'),
('PA166184389','Swissmedic',0,'The Swiss drug labels for sulfadiazin-silber (Flammazine) and Sulfadiazin-Silber, Kombinationen (Ialugen Plus) has a caution for use in patients with known or suspected G6PD deficiency.'),
('PA166184390','Swissmedic',0,'The Swiss drug label for sulfamethoxazole and trimethoprim (Bactrim) cautions about use of the drug in patients with G6PD deficiency.'),
('PA166184391','Swissmedic',0,'The Swiss drug label for sulfasalazine (Salazopyrin) states that the drug is contraindicated in patients with G6PD deficiency.'),
('PA166184392','Swissmedic',0,'The Swiss drug label for tamoxifen (Nolvadex) cautions about changes in efficacy in CYP2D6 poor metabolizers.'),
('PA166184393','Swissmedic',0,'The Swiss drug label for pitavastatin (Livazo) states that genetic variation in SLCO1B1 gene may impact pitavastatin concentration.'),
('PA166184394','Swissmedic',0,'The Swiss drug label for prasugrel (Efient) states that genetic variations of CYP3A5, CYP2B6, CYP2C9 or CYP2C19 have no relevant effect on the pharmacokinetics of prasugrel or its inhibition of platelet aggregation.'),
('PA166184395','Swissmedic',0,'The Swiss drug label for propafenone (Rytmonorm) states that propafenone may be metabolized more slowly in patients with CYP2D6 variants where the 5-hydroxy metabolite is not produced or is produced minimally.'),
('PA166184396','Swissmedic',0,'The Swiss drug label for rabeprazole (Pariet) states that CYP2C19 slow metabolizers may have higher concentration (AUC) as compared to extensive metabolizers.'),
('PA166184402','Swissmedic',0,'The Swiss drug label for ranolazine (Ranexa) states that CYP2D6 poor metabolizers may have higher risk for adverse events.'),
('PA166184403','Swissmedic',0,'The Swiss drug label for rasburicase (Fasturtec) states that rasburicase is contraindicated in patients with G6PD deficiency due to risk of hemolytic anaemia.'),
('PA166184404','Swissmedic',0,'The Swiss drug label for tamsulosin (Pradif) and tamsulosin and dutasteride (Duodart) states that since CYP3A4 inhibitors can significantly influence exposure to tamsulosin in CYP2D6 poor metabolizers, all tamsulosin treated patients should avoid strong CYP3A4 inhibitors.'),
('PA166184405','Swissmedic',1,'The Swiss drug label for brexpiprazole (REXULTI) states that extensive CYP2D6 metabolizers receiving both CYP3A4 and CYP2D6 inhibitors, or slow CYP2D6 metabolizers receiving strong CYP3A4 inhibitors, are expected to have a 4-5-fold increase in brexpiprazole concentrations. Therefore, the dosage of REXULTI in these cases should be reduced to a quarter of the recommended dose.'),
('PA166184421','Swissmedic',0,'The Swiss label for risperidone (Risperdal) states that CYP2D6 plays a role in risperidone metabolism. However, no clinically relevant differences were observed in slow and fast metabolizers.'),
('PA166184422','Swissmedic',0,'The Swiss drug label for tetrabenazine (Xenazine) states that patients should be tested for CYP2D6 poor metabolizer status prior to receiving daily doses above 50 mg.'),
('PA166184423','Swissmedic',0,'The Swiss drug label for Thrombozytenaggregationshemmer, exkl. Heparin (DuoPlavin 75/100 mg) cautions about use in patients with G6PD deficiency.'),
('PA166184424','Swissmedic',1,'The Swiss drug label for thioguanine (Lanvis) cautions about use in patients with a congenital deficiency of the enzyme thiopurine methyltransferase (TPMT).'),
('PA166184425','Swissmedic',0,'The Swiss drug label for tolperisone (Mydocalm) suggests that tolperisone exposure may be increased in CYP2D6 poor metabolizers.'),
('PA166184426','Swissmedic',0,'The Swiss drug label for tolterodine (Detrusitol) gives information on pharmacokinetic changes in CYP2D6 poor metabolizers. This did not result in any changes in safety or tolerability alone but was notable in patients receiving CYP3A4 inhibitors.'),
('PA166184427','Swissmedic',0,'The Swiss drug label for ezetimibe/rosuvastatin (Ezetimib-Rosuvastatin-Mepha Kapseln) states that genetic polymorphisms in SLCO1B1 and ABCG2 may lead to an increase in rosuvastatin exposure, a reduction in the dosage is recommended.'),
('PA166184428','Swissmedic',0,'The Swiss drug label for sertindole (Serdolect) states that sertindole is extensively metabolized by the CYP2D6 and CYP3A, and sertidole concentration may be affected in patients who are CYP2D6 poor metabolizers and in patients simultaneously taking drugs that are CYP2C6 or CYP3A inhibitors.'),
('PA166184429','Swissmedic',1,'The Swiss drug label for ezetimibe/simvastatin (Inegy) states that patients with SLCO1B1 c.521T&gt;C polymorphism are at risk of increased exposure to simvastatin acid, which may lead to an increased risk of rhabdomyolysis. &quot;Genotyping for the presence of the C allele should be considered as part of the benefit-risk assessment in individual patients before prescribing simvastatin 80 mg, and high doses should be avoided in identified carriers of the CC genotype.&quot;'),
('PA166184430','Swissmedic',0,'The Swiss drug label for Simvastatin and Fenofibrate (Cholib) states that the decreased function of hepatic OATP transport proteins may increase systemic simvastatin exposure and the risk for myopathy and rhabdomyolysis.'),
('PA166184434','Swissmedic',0,'The Swiss drug label for sofosbuvir (Sovaldi) states that &quot;consideration should be given to possibly extending the duration of therapy beyond 12 weeks up to 24 weeks, in particular for subgroups with one or more of the previously identified negative predictive factors associated in the past with lower response rates to interferon-containing therapies (e.g. advanced fibrosis/cirrhosis, high initial viral load, black skin, IL28B-Non-CC genotype, earlier non-response to peginterferon alfa and ribavirin).&quot;'),
('PA166184441','Swissmedic',0,'The Swiss drug label for dolutegravir (Julica) states that there is no evidence that gene variants of UGT1A1, CYP3A4, CYP3A5 and NR1I2 have clinically relevant effects.'),
('PA166184442','Swissmedic',0,'The Swiss drug label for duloxetine (Cymbalta) states that CYP2D6 metabolizer status contributes to inter-individual differences in pharmacokinetics.'),
('PA166184443','Swissmedic',0,'The Swiss drug label for efavirenz (Stocrin) states that patients with elevated efavirenz concentrations, such as patients with CYP2B6 genotypes *1/*6 and *6/*6, have a higher risk of prolonging the QTc interval.'),
('PA166184444','Swissmedic',0,'The Swiss drug label for eletriptan (Relpax) states that CYP2D6 polymorphisms have no clinically relevant effect on eletriptan pharmacokinetics.'),
('PA166184445','Swissmedic',1,'The Swiss drug label for escitalopram (Cipralex) states that care should be used in dosing in CYP2C19 metabolizers.'),
('PA166184446','Swissmedic',0,'The Swiss drug label for escitalopram (Cipralex) states that no significant changes in plasma levels were measured in poor CYP2D6 metabolizers.'),
('PA166184447','Swissmedic',0,'The Swiss drug label for fesoterodine (Toviaz) cautions the increased likelihood of side effects in CYP2D6 poor metabolizers.'),
('PA166184448','Swissmedic',0,'The Swiss drug label for flucloxacillin (Floxapen) states that patients carrying the HLA-B*5701 allele have increased risk for drug-induced liver damage although routine testing is not required due to the low positive predictive value.'),
('PA166184449','Swissmedic',0,'The Swiss drug label for flucytosine (Ancotil) cautions about risk for toxicity of flucytosine in patients with DPYD deficiency if nucleoside analogues have been given and states that DPYD testing is indicated. It does not discuss testing in patients receiving flucytosine only.'),
('PA166184450','Swissmedic',0,'The Swiss drug label for fluorouracil (Efudix) requires DPYD testing in patients receiving fluorouracil who have also been treated with brivudine or other nucleoside analogues.'),
('PA166184451','Swissmedic',0,'The Swiss drug label for fluorouracil (Fluorouracil Labatec) cautions about increased toxicity in patients with the 2R/2R and 2R/3R genotypes in the TYMS gene promoter relative to that of 3R/3R individuals.'),
('PA166184452','Swissmedic',0,'The Swiss drug label for fluoxetine (Fluctine) states that the sum of fluoxetine and active metabolites is comparable between CYP2D6 extensive and poor metabolizers.'),
('PA166184453','Swissmedic',0,'The Swiss drug label for fluvoxamine (Floxyfral) states that the pharmacological properties and relative proportions of metabolites of fluvoxamine are altered in CYP2D6 poor metabolizers.'),
('PA166184454','Swissmedic',0,'The Swiss drug label for galantamine (Reminyl) states that CYP2D6 is involved in the metabolism of galantamine but there were limited differences between CYP2D6 extensive and poor metabolizers.'),
('PA166184455','Swissmedic',0,'The Swiss drug label for gefitinib (Iressa) states that CYP2D6 poor metabolizers had increased exposure compared to CYP2D6 extensive metabolizers.'),
('PA166184456','Swissmedic',0,'The Swiss drug label for glibenclamide (Daonil) states that caution should be used when treating patients with G6PD deficiency with glibenclamide as they are at increased risk for hemolytic anemia.'),
('PA166184457','Swissmedic',0,'The Swiss drug label for gliclazide (Diamicron) states that caution should be used when treating patients with G6PD deficiency with gliclazide as they are at increased risk for hemolytic anemia.'),
('PA166184458','Swissmedic',0,'The Swiss drug label for glimepiride (Amaryl) states that caution should be used when treating patients with G6PD deficiency with glimepiride as they are at increased risk for hemolytic anemia.'),
('PA166184459','Swissmedic',0,'The Swiss drug label for Glyceroltrinitrat (Deponit) states that caution should be used when treating patients with G6PD deficiency with glycerol trinitrate (also known as nitroglycerin) due to reduced metabolism.'),
('PA166184460','Swissmedic',0,'The Swiss drug label for haloperidol (Haldol) states that clearance of haloperidol is reduced in CYP2D6 poor metabolizers compared to extensive metabolizers.'),
('PA166184461','Swissmedic',0,'The Swiss drug label for hydroxychloroquine (Plaquenil) states that this drug is contraindicated in patients with G6PD deficiency.'),
('PA166184490','Swissmedic',0,'The Swiss drug label for zuclopenthixol (Clopixol) states that zuclopenthixol is metabolized by the polymorphic CYP2D6 but the clinical significance of poor metabolizer genotypes on metabolite production is not known.'),
('PA166184499','Swissmedic',0,'The Swiss drug label for rosuvastatin (Crestor) states that genetic polymorphisms in SLCO1B1 and ABCG2 may lead to an increase in rosuvastatin exposure, a reduction in the dosage is recommended.'),
('PA166184500','Swissmedic',0,'The Swiss drug label for simvastatin (Zocor® 20 mg/40 mg/80 mg) states that patients with SLCO1B1 c.521T&gt;C polymorphism are at risk of increased exposure to simvastatin acid, which may lead to an increased risk of rhabdomyolysis. &quot;Genotyping for the presence of the C allele should be considered as part of the benefit-risk assessment in individual patients before prescribing simvastatin 80 mg, and high doses should be avoided in identified carriers of the CC genotype.&quot;'),
('PA166184502','Swissmedic',0,'The Swiss drug label for lamivudine / abacavir (Kivexa) states that patients should be screened for the presence of HLA-B*57:01 prior to starting treatment with abacavir. Kivexa is contraindicated in carriers of the HLA-B*57:01 allele.'),
('PA166184504','Swissmedic',0,'The Swiss drug label for zidovudine / lamivudine / abacavir (Trizivir) states that patients should be screened for the presence of HLA-B*57:01 prior to starting treatment with abacavir. Trizivir is contraindicated in carriers of the HLA-B*57:01 allele.'),
('PA166184506','Swissmedic',0,'The Swiss drug label for dolutegravir / abacavir / lamivudine (Triumeq) states that patients should be screened for the presence of HLA-B*57:01 prior to starting treatment with abacavir. Triumeq is contraindicated in carriers of the HLA-B*57:01 allele.'),
('PA166184524','U.S. Food and Drug Administration',0,'The FDA-approved drug label for alpelisib (PIQRAY) states that it is indicated for the treatment of patients with hormone receptor positive, HER-2 negative (ERBB2 negative) and PIK3CA-mutated breast neoplasms.'),
('PA166184539','U.S. Food and Drug Administration',0,'The FDA-approved drug label for paliperidone (INVEGA) states that population pharmacokinetic analyses found no difference in exposure or clearance of paliperidone between extensive metabolizers and poor metabolizers of CYP2D6 substrates.'),
('PA166184560','U.S. Food and Drug Administration',0,'The FDA-approved drug label for ramucirumab (CYRAMZA) states that it is indicated for patients with EGFR or ALK'),
('PA166184561','U.S. Food and Drug Administration',0,'The FDA-approved drug label for ramucirumab (CYRAMZA) states that KRAS status testing was used to stratify patients in the RAISE (NCT01183780) clinical trial of ramucirumab in metastatic colorectal cancer.'),
('PA166184565','U.S. Food and Drug Administration',0,'The FDA label for tafamidis (VYNDAQEL) and (VYNDAMAX) states is it indicated for the treatment of the cardiomyopathy of wild type or'),
('PA166184636','U.S. Food and Drug Administration',0,'The FDA-approved drug label for tipiracil / trifluridine (Lonsurf) states that it is indicated for patients who have failed other targeted therapies including those for KRAS negative metastatic colorectal cancer and HER2 positive (ERBB2) metastatic gastric or gastroesophageal junction cancers. Therefore testing was required for those prior therapies.'),
('PA166184637','U.S. Food and Drug Administration',0,'The FDA-approved drug label for Oxymetazoline and Tetracaine (KOVANAZE) states that patients with G6PD deficiency or congenital methemoglobinemia may be at increased risk for methemoglobinemia when treated with this drug. There is also a warning for pseudocholinesterase deficiency (BCHE) and risk for toxicity which is not listed on the FDA biomarker table.'),
('PA166184754','U.S. Food and Drug Administration',0,'The FDA label for procainamide states that it is metabolized by acetylation, and differences in exposure may occur between fast and slow acetylators. Acetylation status of an individual can be determined by examining genetic variants in the NAT2 gene. However, the label never mentions any specific gene with regard to acetylator status.'),
('PA166184917','U.S. Food and Drug Administration',0,'The FDA-approved drug label for avatrombopag (DOPTELET) states that Avatrombopag is primarily metabolized by CYP2C9.'),
('PA166185145','U.S. Food and Drug Administration',0,'Brentuximab vedotin (ADCETRIS) is a CD30-directed antibody-drug conjugate indicated for treatment of patients with various lymphomas, including patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), and patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.'),
('PA166185151','U.S. Food and Drug Administration',1,'The FDA-approved drug label for amifampridine (RUZURGI) states that NAT2 poor metabolizers have higher concentrations of the drug as compared to normal metabolizers, and that the drug should be initiated at the lowest recommended starting dosage in these patients.'),
('PA166185156','U.S. Food and Drug Administration',0,'The FDA drug label for mivacurium chloride (MIVACRON) states that MIVACRON should be used with great caution, if at all, in patients known or suspected of being homozygous for the atypical plasma cholinesterase gene (BCHE), due to risk of prolonged neuromuscular block following administration of MIVACRON.'),
('PA166185168','U.S. Food and Drug Administration',1,'The FDA-approved drug label for pitolisant (WAKIX) states that dosage reduction is recommended in patients known to be poor CYP2D6 metabolizers because these patients have higher pitolisant concentrations than normal CYP2D6 metabolizers. The maximum recommended dosage is 17.8 mg once daily for poor metabolizers of CYP2D6.'),
('PA166185180','U.S. Food and Drug Administration',0,'The FDA-approved drug label for nusinersen (SPINRAZA) states that nusinersen is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.'),
('PA166185190','U.S. Food and Drug Administration',0,'The FDA-approved drug label for ospemifene (OSPHENA) states that ospemifene is metabolized primarily by CYP3A4 and CYP2C9, and ospemifene was also suggested to be a weak inhibitor for CYP2B6, CYP2C9, CYP2C19, CYP2C8, CYP2D6 and CYP3A4 in in vitro studies.'),
('PA166185194','U.S. Food and Drug Administration',0,'The FDA label for raloxifene (EVISTA) states that EVISTA is indicated for the treatment and prevention of osteoporosis in postmenopausal women, for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and for the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer. The label notes the percentages of patients in clinical studies who had estrogen receptor (ER) positive disease.')